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1. Introduction 
 
1.1. The Immune System 
The defense mechanism of vertebrates and, in particular, mammals against pathogens 
depends on their immune system (Latin: immunis: exempt). For example, in response to an 
attack by infectious agents, the immune system must combat and destroy the “danger” and 
maintain the homeostatic balance of the body. The entities that define a successful immune 
defense against an infectious disease are the immunological arms of protection. The 
immune system can simplistically be divided into two components namely, the innate and 
the adaptive immune systems (Hoffmann et al., 1999). The successful immune defenses 
against an infectious agent are the outcome of the close interaction between these two main 
parts of the immune system. 
 
1.1.1. The Innate System 
The first phase of host defense against invading microorganisms relies on the innate arm of 
the immune system, an evolutionary ancient and universal form of host protection. It has 
been traditionally considered an immediate but non-adaptive response to infection or tissue 
injury (Fearon et al., 1996). The innate immune system is composed of numerous and 
variable components. The skin, mucosal secretions, and stomach and intestinal pH are 
physical/chemical barriers that form the first line of defense. When an infectious agent 
evades these barriers and invades the host, cellular innate immune defense come into play 
that includes natural killer (NK) cells, granulocytes, γδ T lymphocytes, macrophages and 
dendritic cells (DCs). Although cellular defenses of innate immune responses do not 
recognize specific epitopes on an antigen in the manner observed with the specific immune 
responses, they do rely heavily on a limited number of highly conserved cellular receptors 
termed pathogen-recognition receptors (PRRs) which detect common molecular structures 
associated with many classes of pathogens; these elements have been termed pathogen-
associated molecular patterns (PAMPs). This allows the immune system to discriminate 
between infectious non-self and non-infectious self (Janeway et al. 2002). Besides 
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physical/chemical barrier and cellular components, innate responses also comprise a 
number of soluble factors. These factors include the complement components, natural 
antibodies, LPS-binding protein (LBP), mannan-binding protein, acute phase proteins, 
certain chemokines and cytokines, prostaglandins and leukotrienes. 
 
The success of the innate immune system in controlling pathogens is highlighted by the fact 
that all organisms except for the vertebrates rely exclusively on innate immune responses. 
Even vertebrates cope with most infections by exclusively using their innate immune 
system. Under some circumstances, however, the invading pathogen escapes innate 
immune surveillance. In which case, the adaptive immune response is launched in order to 
support the innate responses with increased specificity and the ability to generate memory. 
 
1.1.2. The Adaptive System 
The adaptive immune response is associated with the activation of B and T lymphocytes 
which constitute the cellular elements of the adaptive immune system. Unlike cells of 
innate system, which use a fixed repertoire of inherited receptors, B and T cells undergo a 
somatic recombination of germ line encoded antigen receptor gene segments to create new 
and unique antigen receptors (Tonegawa, 1983; Tonegawa, 1988) capable of recognizing 
virtually any antigen. Cells expressing an antigen-specific receptor are selected upon 
pathogen binding since receptor triggering induces clonal expansion by proliferation. 
Furthermore, cell clones selected for a certain antigen are retained, thus constituting antigen 
specific memory. 
 
Antibodies, encoded by heavy and light immunoglobulin (Ig) genes, are expressed by B 
cells in a soluble and membrane bound form and serve as the antigen receptors. Secreted 
antibodies are the main effectors of the humoral response. They recognize antigens in their 
native three-dimensional structure, thus every chemical structure can serve as an antigenic 
epitope for B cells. Unlike B cell receptors (secreted or membrane bound antibodies), T cell 
receptors (TCR) are never secreted and they recognize peptides produced by the proteolytic 
cleavage of antigens. Thus, T cells recognize the primary structure (amino acid sequence), 
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and B cells recognize the tertiary structure (three-dimensional) of a protein. Moreover, T 
cells recognize antigenic peptides only when they are presented by antigen-presenting cells 
(APCs), which include monocytes, macrophages, endothelial cells, fibroblasts, fibrocytes, 
DCs (Guermonprez et al., 2002; Knight et al., 1993) on the surface bound to Major 
Histocompatibility Complex (MHC) class I and II proteins (Davis et al., 1998). B cells can 
also function as APCs, but not for stimulating naïve T cells in primary immune response 
(Finkelman et al., 1992). Intracellular antigens (present in cytosol) are processed to a length 
of 8-10 amino acids by the proteosome and are loaded onto MHC class I molecules which 
are then delivered to the cell surface, where they are recognized by CD8+ T cells (Flutter et 
al., 2004). In contrast, extracellular antigens internalized in endosomal compartments are 
processed in the lysosomes, giving rise to peptides of 12–24 amino acids in length 
(Chapman, 2006), which are loaded onto MHC class II molecules. These are then delivered 
to the cell surface for recognition by CD4+ T cells (Abbas et al., 1996). 
 
Together, appropriate innate and adaptive system interactions are needed for highly 
efficient recognition and clearance of pathogens which could confer optimal protection to 
host against the invading pathogens.  
 
1.2. Dendritic Cells: The Central Link between Innate and Adaptive 
Immune System 
The signals obtained from the recognition of an invading pathogen by the cellular arm of 
the innate immune system must be conveyed to the cells of the adaptive immune system in 
order to mount an effective immune response. This crucial task is efficiently fulfilled by 
APCs, in particularly by DCs, which provide T cells not only with microbial antigen (once 
processed) but also with the full information about the nature of the pathogen, thus bridging 
the essential connection between innate and adaptive immunity (Palucka et al., 1999; 
Banchereau and Steinman, 1998). DCs are professional antigen presenting cells which play 
a pivotal role in immunosurveillance against the microbial infections.  
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1.2.1. Dendritic Cells: Origin and Distribution 
In 1970s, Ralph M. Steinman and Zanvil A. Cohn first identified and described the DCs as 
a novel cell population in the peripheral lymphoid organs of mice (Steinman and Cohn, 
1973; Steinman and Cohn, 1974; Steinman et al., 1975). Subsequently, DCs have been 
described in more and more tissues. Nowadays, it is thought that most organs possess their 
own DC populations (Hart, 1997). DCs belong to the heterogeneous group of cells that 
possess varying anatomical location, cell surface markers and function. However, most 
DCs have several features in common (Table 1).  
 
Table 1: List of common features of dendritic cells  
 
1.) DCs originate from HSCs in bone marrow and migrate to various tissues via bloodstream and reside 
there as immature cells.  
2.) Immature DCs capture antigen or encounter danger signals triggered by infectious agents through 
receptor and non-receptor-mediated mechanisms and then mature during migration to the secondary 
lymphoid organs. 
3.) Depending on the specific environmental signal, DCs differentiate into different maturation forms. 
4.) Mature DCs lose the phagocytic activity and express high density of MHC class I and II and 
costimulatory molecules to stimulate naïve CD4+ and CD8+ T cells into T helper (Th) cells and cytotoxic 
T lymphoctes (CTL), respectively.  
5.) The particular maturation form of DCs determines the fate of Th cell amplification into Th1, Th2 or 
Treg lymphocytes. 
 
The development of DCs is considered to occur in distinct stages. Hematopoietic 
pluripotent stem cells (HSCs), under the influence of yet unknown factors, constantly 
generate DCs progenitors in the bone marrow, which give rise to circulating precursors in 
the blood (Wu and Dakic, 2004). These DCs precursors are then seeded via the bloodstream 
to a large variety of tissues where they reside and give rise to immature DCs which possess 
high endocytic and phagocytic activity (Banchereau et al., 2000). DCs are a sparsely 
distributed group of cells constituting about 1-2% of total cells and are present nearly in all 
organs like, thymus, heart, kidney, lung, intestine, lymph nodes, spleen, skin etc. In the last 
two decades, with the help of monoclonal antibodies against multiple surface molecules of 
the diverse DCs subtypes both in human and mouse have been described (Shortman and 
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Liu, 2002, Wan and Dupasquier, 2005). DCs subsets have been investigated in both 
lymphoid organs (thymus, bone marrow, spleen, lymph nodes, tonsils etc.) and non-
lymphoid organs (blood, skin etc.). In the mouse spleen, conventional DCs express high 
levels of CD11c (the integrin-αx chain) and have been divided into three subtypes on the 
basis of their expression of CD4 and CD8α, namely CD4-CD8α+, CD4+CD8α- and CD4-
CD8α- (Vremec et al., 2000). These subsets are present in different percentages in the 
spleen. In the total population of CD11c+ splenic DCs, CD4+CD8α- DCs are ~50% while 
CD4-CD8α+ and CD4-CD8α- DCs are ~25% each (Vremec et al., 2000). CD4-CD8α+ DCs 
are mainly concentrated in the T cell areas in the spleen while CD4+CD8α- and CD4-CD8α- 
DCs are concentrated in the marginal zones of the spleen, but migrate into the T cell zones 
on stimulation with microbial products. It has been shown that CD4-CD8α+ DCs have the 
ability to produce large amounts of IL-12 as compared to CD4+CD8α- and CD4-CD8α- 
DCs (Hochrein et al., 2001). There exist contradictory reports regarding the functional 
properties of these subsets. Therefore, exact functional differences between these subsets 
are at present unclear. 
 
1.2.2. Dendritic Cells: Maturation and Migration 
When the immature DCs encounter any antigen/pathogen in peripheral tissues, they 
undergo a change in their phenotype and function which culminate in the complete 
transition from antigen-capturing cells to antigen-presenting cells. This transition results in 
the maturation of DCs and their migration from peripheral tissues to the lymphoid organs 
such as the lymph nodes. As these two events are critical in the life cycle of DCs, they are 
discussed below together. 
 
1.2.2.1. Dendritic Cells: Activation and Maturation 
Numerous factors are involved in DCs activation and transition of immature DCs into 
mature DCs which includes pathogen-specific PAMPs such as LPS, PGN, bacterial DNA, 
double stranded RNA (dsRNA) (Guermonprez et al., 2002). Moreover, the balance between 
pro- and anti-inflammatory cytokines in the local microenvironment, including TNF-α, IL-
1β, IL-6, IL-10, TGF-β and prostaglandins (Banchereau et al., 2000; Kalinski et al., 1998) 
 6 
also induces DCs maturation. Furthermore, certain T cell-derived signals, such as CD40L, 
play a role in the maturation process (Cella et al., 1996). All these factors can induce 
immature DCs to mature and migrate to the secondary lymphoid organs where they present 
captured and processed antigen to naïve T lymphocytes. 
 
Immature DCs are efficient in capturing and processing antigen to form MHC peptide 
complexes while mature DCs are efficient in presenting the processed antigen and thus 
prime T cell responses (Banchereau et al., 2000). Besides these properties immature and 
mature DCs possess numerous other features, figure 1 shows some of them. 
 
 
Figure 1: Some features of immature and mature DCs. 
 
 
LPS, TNF-α, CD40L 
IL-10 
Immature 
• High endocytic and phagocytic 
activity for antigen capture. 
• High antigen processing capacity. 
• Low antigen presentation capacity. 
• Cytoplasmic MHC class II. 
• High CCR1, CCR2, CCR5, CCR6, 
CXCR1, CXCR4 and low CCR7 
(Chemokine receptor molecules). 
• Low CD40, CD80, CD86 (co-
stimulatory molecules). 
• Low LFA-3/CD58, ICAM-1/CD54 
(adhesion molecules). 
• High CD68. 
• No DC-LAMP. 
• T cell stimulation low/absent. 
• No/less IL-12 secretion. 
• Low endocytic and phagocytic 
activity for antigen capture. 
• Low antigen processing capacity. 
• High antigen presentation capacity. 
• Membrane MHC class II. 
• Low CCR1, CCR2, CCR5, CCR6, 
CXCR1, CXCR4 and high CCR7 
(Chemokine receptor molecules). 
• High CD40, CD80, CD86 (co-
stimulatory molecules). 
• High LFA-3/CD58, ICAM-1/CD54 
(adhesion molecules). 
• Low CD68. 
• High DC-LAMP.  
• High T cell stimulation capacity. 
• High IL-12 secretion. 
Mature 
 7 
1.2.2.2. Dendritic Cells: Migration 
Following activation, DCs migrate to the lymphoid organs such as the lymph nodes. There, 
DCs attract lymphocytes by releasing various chemokines and maintain the viability of 
recirculating T lymphocytes (Caux et al., 2002; Sozzani, 2005). DCs migration in vivo is a 
tightly regulated function of maturation and is controlled by a variety of cytokines and 
chemokines (e.g. GM-CSF, TNF-α, IL-1, MIP-1α and β), but also nonchemokine 
chemotactic agonists, lipid mediators and membrane proteins affect DCs movement and 
maturation (Sozzani, 2005). During maturation, DCs upregulate CCR7, a receptor for 
chemokines CCL19 (MIP-3β) and CCL21 (secondary lymphoid tissue chemokines, SLC) 
(Dieu et al., 1998) and drives DCs migration to the lymphoid vessels and T cells areas of 
secondary lymphoid organs. As CCR7 also mediates the homing of T cells to secondary 
lymphoid organs, it plays a key role in helping antigen-bearing DCs to encounter responder 
T cells (Willimann et al., 1998). 
 
1.2.3. DC-T cell Interactions 
Once DCs reach the secondary lymphoid organs such as the spleen and the lymph nodes, 
they prime T cell responses. DCs present captured antigen to naïve T cells (Thery and 
Amigorena, 2001), thereby inducing activation and differentiation of naïve CD4+ and 
CD8+ T cells into T helper (Th) cells and cytotoxic T lymphocytes (CTL), respectively. For 
T cells to get efficiently activated, they require three signals (Lipscomb and Masten, 2002), 
namely: 
Signal 1: CD4+ and CD8+ T cells need to recognize the displayed antigen on MHC class II 
& MHC class I molecules, respectively. Each T cell carries a unique T cell receptor & only 
those T cells that recognize the antigens presented by DCs will become activated (Fig. 2).  
Signal 2: T cells need some accessory molecules on DCs known as costimulatory 
molecules that DCs have upregulated during maturation. This signal makes the T cells to 
divide and differentiate into effector T cells. In the absence of sufficient costimulation 
signal, T cells undergo anergy or apoptosis (Fig. 2). 
Signal 3: Besides these two signals, a third signal is required to activate T cells. This signal 
is most probably delivered in the form of soluble molecules such as cytokines and 
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chemokines, which are produced by DCs themselves and directly affect T cells in a 
paracrine manner. For example secretion or lack of secretion of IL-12 plays a key role in 
the final differentiation of naïve Th cells into Th1-type or Th2-type effector cells, 
respectively (Fig. 2). 
 
Figure 2 illustrates a model for explaining close interaction between DCs and T cells using 
CD4+ T cells (Th cells) for the development of a protective immune response. This 
communication between DCs and Th cells is a dialogue rather than a monologue. Th cells 
respond to DCs and vice versa. The polarization of Th cells towards Th1-type or Th2-type 
is depending upon the type of signal 3 produced by DCs in response to the interaction of 
pathogen-specific PAMPs with specialized PRRs on the surface of DCs (Kapsenberg, 
2003) (Fig. 2).  
 
Dendritic cell   CD4+ T cell 
Signal 1 Peptide-MHC II  TCR and CD4 
Signal 2 CD40    CD40L 
CD80    CD28/CTLA-4 
CD86    CD28/CTLA-4 
Signal 3 IL-12 production  Th1-type response 
No IL-12 production  Th2-type response 
IL-10 production  Treg-type response 
TGF-β production  Treg-type response 
 
Figure 2: Model for DC-CD4+ T cell interaction. 
Naive Th Cell 
Dendritic Cell 
CD80/86 
CD40 
Peptide -MHC II 
CD28 
CD40L 
TCR 
Th1 
Th2 
IFN-γ 
IL-2 
IL-5 
IL-4 
IL-13 
Signal  1 
Signal  2 
Signal  3 
TNF-β 
CD4 
PRRs 
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1.2.4. Dendritic cells: Production of Cytokines and Chemokines 
On maturation, DCs secrete a number of soluble factors such as cytokines and chemokines 
that are critical in determining the nature of the ensuing immune response. Their rate of 
secretion varies with the maturation state of DCs. DCs produce various cytokines such as 
IL-12 (Sundquist et al., 2003), IL-10 (Jiang et al., 2002), IL-18, TNF-α, IFN-γ, IL-2, IL-6 
etc. in response to bacterial stimuli. Many cytokines act in an autocrine fashion and are 
involved in the activation or suppression of DCs effector functions, such as TNF-α, IL-1β, 
IL-6, IL-12 or IL-10. IL-12 is important for the promotion and maintenance of Th1 
differentiation and for the initiation of IFN-γ-dependent cell-mediated immunity to many 
intracellular pathogens (Trinchieri, 1995). The production of IL-10 by DCs inhibits Th1 
responses by inhibiting the full maturation of DCs and their capacity to produce IL-12 
(Steinbrink et al., 1997) and also promotes the development of regulatory T cells (Wakkach 
et. al., 2003). IFN-γ is a potent adjuvant of Th1 responses and primes DCs to produce 
enhanced levels of IL-12 and thus promotes the development of Th1 responses (Snijders et 
al., 1998). In addition to the production of cytokines, maturation of DCs is also inducing 
secretion of chemokines that recruit monocytes, DCs (Nakamura et al., 1995), and specific 
subsets of T cells into the local environment. Mature DCs are known to produce multiple 
chemokines, including MCP-1/CCL2, CCL3/MIP-1α, CCL5/RANTES, CXCL8 and 
CXCL10 (Sallusto et al., 1998; Sozzani, 2005). MCP-1 is rapidly produced by DCs upon 
TLR activation and binds to CCR2, the only known functional receptor. Besides attracting 
leukocytes, MCP-1 is also known to inhibit Th1 responses and promotes the development 
of Th2 responses in both infectious (Chensue et. al., 1996; Matsukawa et al., 2000) and 
allergic disease models (Gonzalo et al., 1998).  
 
In summary, DCs can produce several different cytokines and chemokines and thereby 
exert important quality control on the immune system. 
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1.3. Sepsis 
Sepsis (in Greek Σήψις, putrefaction) is defined as a systemic inflammatory response 
syndrome (SIRS) initiated by infection that resulted in a disruption of inflammatory 
homeostatis. Inflammatory dysregulation consequently affects multiple organs via effects 
on endothelial, epithelial and immune cell types that leads to irreversible damage (Fig. 3).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Pathogenesis of sepsis (Adapted from Buras et al., Nat Rev Drug Disc, 4, 854-65). 
 
The poor outcome in sepsis is considered to be a consequence of an overactive systemic 
inflammatory response elicited by the invading micro-organisms (Ruokonen et al., 1991). 
The development of SIRS is countered by a mechanism to terminate inflammation 
following elimination of the infectious agent. This counter regulatory mechanism is known 
as compensatory anti-inflammatory response (CARS) (Bone et al., 1996). SIRS and CARS 
are associated with the release of pro- and anti-inflammatory molecules, respectively 
(Cavaillon et al., 1998). Imbalance and overreaction of either response can result in host 
damage caused by excessive inflammation or immune dysfunction and thus play a decisive 
role for the outcome of sepsis (Fig. 4).  
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Figure 4: Role of SIRS and CARS in the development of sepsis (Adapted from Buras et al., Nat Rev Drug 
Disc, 4, 854-65). 
 
Cecal ligation and puncture (CLP) in mice develop symptoms similar to those found in 
septic patients and serve as a model for polymicrobial sepsis. Pro- and anti-inflammatory 
cytokines are expressed in large amounts after CLP, and the balance of their expression 
seems to be critical for the outcome of sepsis (Scott et al., 2002; Torres and De Maio, 
2005). IL-12 and its counterpart IL-10 play a major role during sepsis, as modulation of 
these cytokines influences sepsis-induced mortality after CLP in mice. Application of 
recombinant IL-10 prior to CLP increases survival (Walley et al., 1996), administration of 
IL-12 increases sepsis-induced mortality (Echtenacher et al., 2001). However, the time of 
intervention appears to be decisive for disease development. Absence of IL-10 during the 
initial phase of sepsis is detrimental (Latifi et al., 2002), whereas neutralization of IL-10 at 
later time-points is beneficial (Ayala et al., 2001). In addition to the predominance of anti-
inflammatory mediators, T as well as B lymphocytes undergo apoptosis in the spleen and 
other lymphoid organs during sepsis (Hotchkiss et al., 2001). The remaining T cells display 
reduced responsiveness to mitogens in terms of proliferation and secretion of IL-12 and 
TNF-α, IL-1, 
Chemokines, 
IL-6, IL-12 
IL-10, IL-4, 
IL-18, TGF-β, 
IL-1ra 
TNF-α, IL-1, 
Chemokines, 
IL-6, IL-12 
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IL-18, TGF-β, 
IL-1ra 
Sepsis progression 
Balanced response 
Septic shock/organ 
dysfunction 
SIRS 
CARS 
SIRS CARS 
•Leukocyte activation 
•Sepsis-associated 
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IFN-γ (Ayala et al., 1994). This status of dysregulation of a broad range of the innate and 
adaptive immunity during sepsis has been entitled with terms such as “immunoparalysis”. 
It has to be emphasized that the changes of the immune system observed during 
polymicrobial sepsis cannot be simply reduced to effects mediated by bacteria-derived LPS. 
Mice, which are defective in the LPS signaling molecule Toll-like receptor 4, are 
susceptible to polymicrobial sepsis but not to LPS-induced shock (Echtenacher et al., 
2001). T cell suppression is observed upon polymicrobial sepsis but not upon infusion with 
LPS (Ayala et al., 1994). These findings demonstrate that multiple factors contribute to 
polymicrobial sepsis-mediated immunomodulation. Although being a well-described 
phenomenon, the basic mechanisms leading to sepsis-mediated immunoparalysis have not 
yet been characterized completely. It has been hypothesized that DCs play a pivotal role in 
sepsis-mediated immunosuppression. DCs possess high potential for antigen capture, 
processing and presentation and thus play an important role in orchestrating the body’s cell 
mediated immune response by activating T lymphocytes (as discussed above). Any defects 
in the cascade of DCs antigen capture, processing and presentation will result in the 
impairment of the body’s ability to clear invading microorganisms such as that seen with 
sepsis. 
 
1.4. Sepsis and Dendritic cells 
Much is known on the role of DCs against the invading microorganisms and this 
knowledge is expanding by each passing day but little is understood about the effects of 
polymicrobial sepsis on DCs. Although the potential role played by DCs in the sepsis 
response is fairly obvious, our understanding of its contribution to sepsis pathogenesis is 
fairly limited. The limited knowledge in the field of sepsis and DCs may be attributed to the 
large number of factors involved in the sepsis syndrome. A large number of studies have 
been conducted to show if DCs are truly the cornerstone in modulating this disease process. 
Much of the knowledge what we have today about the role of DCs in the inflammatory 
response comes from studies done in mice models of endotoxemia using bacterial LPS. 
Although mice endotoxemia model does not recapitulate the sepsis response as seen with 
mice CLP model (Echtenacher et al., 2001; Remick and Ward, 2005), it does provide a 
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good model to explore how DCs behave to microbial products and, presumably, microbial 
invasion. In the last few years several studies were published on the role of DCs during 
sepsis response in human patients and mice CLP model. In 2002, Hotchkiss et al. reported 
that the patients who died from sepsis had lost DCs from the spleens (Hotchkiss et al., 
2002). The depletion of DCs was further described in spleen (Tinsley et al., 2003; Ding et 
al., 2004), lymph nodes (Efron et al., 2004), lung (Benjamim et al., 2004) and peritoneum 
(Ding et al., 2004) in mice CLP model for polymicrobial sepsis. Recently, it was found that 
the intrapulmonary instillation of bone marrow-derived DCs prevented lethal Aspergillosis 
infection in septic animals (Benjamim et al., 2004). Also, targeted depletion of 
CD11chiMHCIIhi DCs dramatically increases mortality to sepsis induced by CLP, while 
adoptive transfer with wildtype bone marrow-derived DCs restores survival in this model of 
polymicrobial sepsis (Scumpia et al., 2005), suggesting the involvement of DCs during 
sepsis response. 
 
Besides DCs depletion, their functional properties are also affected by environmental 
factors such as pro- and anti-inflammatory cytokines seen in sepsis. IL-12 is a pro-
inflammatory cytokine, which modulate host immune response. DCs are the major 
producers of IL-12 (Cella et al., 1996). It was described that splenic DCs from septic mice 
showed reduced ability for IL-12 production while the peritoneal DCs produced 
significantly higher amounts of IL-12 than control mice (Ding et al., 2004). Reduced 
production of IL-12 and TNF-α on the one hand and increased production of IL-10 on the 
other was seen in isolated lung DCs from septic mice when stimulated with TLR ligands 
such as LPS, Pam3cys or Shistosoma mansoni eggs (SEA) compared with similarly 
activated DCs obtained from sham mice (Benjamim et al., 2004), suggesting the change in 
DCs cytokine profile towards the Th2-type. Further, studies were performed in order to 
investigate the change in expression of DCs surface costimulatory molecules during sepsis, 
which is a hallmark for DCs activation and maturation. Recently, Ding et al., reported no 
change in CD40, CD80 and CD86 expression by splenic DCs 24 h after CLP. However, in 
peritoneum, DCs showed slightly increased expression of CD86 (statistically not 
significant) while CD40 and CD80 remained the same at 24 h after CLP (Ding et al., 2004). 
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Similarly, no significant difference was observed in the percentage of mature DCs (MHC 
IIhi and CD86hi) in the lymph nodes of CLP versus sham operated mice (Efron et al., 2004). 
In another study with lung DCs, no marked differences in the expression of CD40 and 
CD80 were observed between CLP and sham operated animals (Benjamim et al., 2004). 
The splenic DCs from septic mice with no significant change in their expression of 
costimulatory molecules was found to have similar antigen presenting capacity as that of 
DCs from sham mice while peritoneal DCs with slightly increased expression of CD86 
showed enhanced T cell proliferation capacity (Ding et al., 2004), suggesting the putative 
role of DCs maturation in triggering effective T cell response in order to clear the bacterial 
load. 
 
Although not present in very large number and not really the true effector cell in the body, 
the DC is an integral part of the immune system. The unique ability of DCs to link innate 
and adaptive immunities allows the researchers to study its functional properties in more 
detail and to manipulate DCs to cure many disease processes such as sepsis. Increasing 
evidences suggested the essential role of DCs in sepsis (Efron and Moldawer; 2003) and 
has opened the way to utilize DCs in the treatment of sepsis, whether as a vector, a direct 
effector, or both. 
 
1.5. Aim of the Study 
Sepsis is defined as the combination of SIRS and systemic infection. It is associated with 
immune suppression mediated by a predominance of anti-inflammatory cytokines like IL-
10 and profound loss of lymphocytes through apoptosis. It is well known that DCs possess 
the unique ability to link the innate and adaptive immune systems and play a pivotal role in 
the defense mechanism against infectious diseases. This is primarily achieved by the ability 
of DCs to capture and present antigen to T lymphocytes by migrating to the draining 
lymphoid organs, where they initiate the primary immune response. Numerous scientific 
investigations have also demonstrated the critical role played by DCs in infectious diseases 
both in vitro and in vivo. However, the role of DCs in sepsis-induced immunosuppression 
remains unclear. Therefore, to address this uncertainty, a set of experiments were designed 
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to analyze the influence of polymicrobial sepsis on the phenotypic and functional behavior 
of DCs. 
 
The objective of the present study was to characterize DCs in terms of their number, subset 
composition, expression of surface markers, cytokine release and T cell stimulatory 
capacity during sepsis. 
 
Further, depending upon the changes in their phenotypic and functional properties during 
sepsis, it might be possible to develop a therapy using competent BMDCs that can help to 
overcome the sepsis-induced immunosuppression. 
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2. Materials and Methods 
 
2.1. Animals 
Naïve female BALB/c (wild type), C57BL/6J (wild type) (Harlan Laboratories, Borchen, 
Germany), and BALB/c (IL-12p35-/-) (kindly provided by Gottfried Alber, Institute of 
Immunology, University of Leipzig, Leipzig, Germany) (22.0-24.0 g) were used in the 
present study. All animals were 8-10 weeks old and were allowed to habituate to the animal 
laboratory conditions for at least one week before starting the experiments. Animals were 
housed in a group of five in standard plastic laboratory cages with a wire mesh lid. Cages 
were kept in an air-conditioned, sound-proof room at an ambient temperature of 24.0 ± 
0.5°C. The animals had access to standard lab chow and tap water ad libitum. A 12 hour 
light/dark cycle was maintained throughout the experiments. All animal procedures were 
carried out following institutional guidelines at the Medical Faculty, University of 
Duisburg-Essen, Germany. 
 
2.2. Animal Model for Polymicrobial Sepsis 
Female BALB/c mice were used to induce intra-abdominal polymicrobial sepsis using 
Cecal Ligation and Puncture (CLP) model for sepsis with slight modifications. This model 
of sepsis was developed by the group of Dr. Chaudry (Wichterman et al., 1980) and has 
been used as a standard model for sepsis for more than three decades. The introduction of 
CLP model is considered to be of great relevance for sepsis research. The CLP technique 
comprises of midline laparotomy followed by exposure of cecum, its ligation and puncture. 
CLP leads to polymicrobial peritonitis; bacteraemia and cytokine responses caused by 
leakage of faecal material, and mimic the human scenario of ruptured gut. This technique 
has achieved world wide popularity because of its ease, reproducibility and similarity to 
human disease progression. 
 
A light anaesthesia was introduced by intra muscular injection of the mixture of Ketamin 
(0.1 mg/g body weight of the animal) (CEVA, Sante Animale, Duesseldorf, Germany) and 
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Xylazin (0.01 mg/g body weight of the animal) (CEVA, Sante Animale). Following 
anaesthesia, a mid-line laparotomy was performed and the cecum was exposed. The 
exposed cecum was further ligated at half of its length (50% ligation) with a 5-0 suture 
(Prolene, Norderstedt, Germany) below the ileocecal valve and was punctured once with a 
17-gauge needle (KLINIKA, Usingen, Germany) (Fig. 5). The cecum was then gently 
squeezed to extrude small amount of faeces from the perforation site and after that cecum 
with the gut content was returned back to the peritoneal cavity and the mice were 
resuscitated with 1.0 ml of 0.9% of saline intra peritoneal (i.p.).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: The experimental model for polymicrobial sepsis: cecal ligation and puncture (CLP) (Adapted from 
Buras et al., Nat Rev Drug Disc, 4, 854-65) 
 
Thereafter, the abdomen was closed in a two layer technique with a 5-0 suture. Sham 
animals underwent a laparotomy without CLP. Finally, animals were returned to their cages 
with free access to food and water. This model leads to severe polymicrobial sepsis with a 
mortality rate of about 60-70% within 36 hours.  
 
2.3. Culture Medium, Chemicals, Reagents, Antibodies and Buffers 
All chemicals and reagents used throughout this work were of reasonable purity and 
purchased from different companies as mentioned below. All solutions and lab ware for cell 
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cultures were autoclaved or filtered sterile. All reagents were free of detectable 
lipopolysaccharide (LPS) contaminations as tested using Limulus amoebocyte assay (Bio 
Whittaker, MD, USA). All numbers given in percent (%) refer to either weight per volume 
or, in cases of liquids, to volume per volume. 
 
2.3.1. Culture Medium 
Very Low Endotoxin medium VLE RPMI 1640 (Biochrom, Berlin, Germany) containing 
10% heat-inactivated Fetal Calf Serum (FCS) (Sigma, Deisenhofen, Germany and 
Biochrom), 10 mM HEPES (BioChrom), 2 mM L-Glutamine (Biochrom), 0.06 mg/ml 
Penicillin (Sigma), 0.02 mg/ml Gentamicin G (Sigma), and 0.05 mM 2-Mercaptoethanol 
(Sigma) was used as culture medium (CM). 
 
2.3.2. Chemicals  
7-aminoactinomycin D (7-AAD)  Molecular Probes, Karlsruhe, Germany 
Ammonium Chloride (NH4Cl)  Fluka, Deisenhofen, Germany 
Buffer, Reference standard, pH 4, 7 and 10 Sigma 
Calcium Chloride (CaCl2)   Sigma 
Cytofix/CytopermTM    BD Biosciences, Heidelberg, Germany 
di-Sodium EDTA    Promega, Mannheim, Germany 
Ethylenediaminetetraacetic acid (EDTA) Sigma 
FACS Flow     BD Biosciences 
GolgiStopTM (monensin)   BD Biosciences 
HCl (32%)     Merck, Darmstadt, Germany 
Isofluran     DeltaSelect, Munich, Germany 
LiberaseTM Blendzyme 2   Roche, Grenzach-Wyhlen, Germany 
Magnesium Chloride (MgCl2)  Merck 
di-Sodiumhydrogen Phosphate  Merck 
Sodium Azide      Merck 
Sodium Chloride (NaCl)   Merck 
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Sodium Hydroxide Pellets   Merck 
Perm/WashTM Buffer    BD Biosciences 
Phosphate Buffer Saline Dulbecco’s  Gibco, Karlsruhe, Germany 
Potassium Hydrogen Carbonate (KHCO3) Fluka, Deisenhofen, Germany 
Potassium Chloride (KCl)   Merck 
TBST      Sigma 
VybrantTM CFDA SE Cell Tracer Kit  Molecular Probes 
 
2.3.3. Reagents 
Recombinant mouse granulocyte-monocyte colony-stimulating factor (rmGM-CSF), CD40 
ligand (CD40L), Interleukin-10 (IL-10) and Interferon-γ (IFN-γ) were purchased from 
R&D systems, Wiesbaden, Germany. Synthetic phosphorothioated CpG 1668 
oligonucleotides (Sparwasser et al., 1997) (sequence TCCATGACGTTCCTGATGCT) 
were purchased from Operon, Cologne, Germany. Bovine Serum Albumin (BSA), 
Lipopolysaccharide (LPS, E.coli 026:B6), Ionomycin, Concanavalin A (Con A), Dimethyl 
Sulphoxide (DMSO) and Phorbol 12-Myristate 13-Acetate (PMA) were purchased from 
Sigma. 
 
2.3.4. Antibodies 
All antibodies were purchased from BD Biosciences, ebioscience (Frankfurt, Germany), 
R&D Systems or Immunotools (Friesoythe, Germany). 
 
2.3.4.1. Purified Monoclonal Antibodies 
 
Antibody                           Clone                    Specificity            Isotype                            Company 
 
anti-CD16/CD32  2.4G2  Mouse                    Rat IgG2b, κ  BD Pharmingen 
anti-IL-10  JES5-16E3 Mouse                    Rat IgG2b, κ  BD Pharmingen 
anti-IL-10  JES052A5 Mouse                    Rat IgG1  R&D Systems 
anti-CD3  17A2  Mouse                    Rat IgG2b, κ  BD Pharmingen 
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2.3.4.2. Fluorescent Dye Labeled Monoclonal Antibodies 
 
Antibody-Labeled               Clone                                     Isotype                                             Company 
 
anti-CD3e                              FITC145-2C11                      Armenian Hamster IgG1, κ              BD Pharmingen 
anti-CD4 FITC                      YTS 191.1.2                          Rat IgG2b                                          Immunotools 
anti-CD4 FITC                      RM4-5                                   Rat (DA/HA) IgG2a, κ                      BD Pharmingen 
anti-CD4 PE                          RM4-5                                   Rat (DA) IgG2a, κ                             BD Pharmingen 
anti-CD8a FITC                    53-6.7                                    Rat (LOU/Ws1/M) IgG2a, κ              BD Pharmingen 
anti-CD11b PerCP-CY5.5     M1/70                                   Rat (DA) IgG2a,κ                              BD Pharmingen 
anti-CD11c APC                   N418                                      Armenian Hamster IgG                    eBioscience 
anti-CD11c APC                   HL3                                       Armenian Hamster IgG1, λ               BD Pharmingen 
anti-CD11c PE                      HL3                                       Armenian Hamster IgG1, λ               BD Pharmingen 
anti-CD25 APC                     PC61                                     Rat (Outbred OFA) IgG1, λ              BD Pharmingen 
anti-CD40 FITC                    HM40-3                                 Armenian Hamster IgM, κ               eBioscience 
anti-CD40 FITC                    3/23                                       Rat (LOU) IgG2a, κ                           BD Pharmingen 
anti-CD69 PE                        H1.2F3                                  Armenian Hamster IgG1, λ               BD Pharmingen 
anti-CD80 FITC                    16-10A1                                Armenian Hamster IgG2, κ               BD Pharmingen 
anti-CD86 PE                        GL1                                       Rat (LOU) IgG2a, κ                          BD Pharmingen 
anti-B220 PE                         RA3-6B2                               Rat IgG2a, κ                                      BD Pharmingen 
anti-Gr-1 FITC                      RB6-8C5                               RatIgG2b                                            Immunotools 
anti-H-2Kd PE                       SF1-1.1                                  Mouse(SJL) IgG2a, κ                        BD Pharmingen 
anti-IA/IE Biotin                   2G9                                        Rat (DA/HA) IgG2a, κ                      BD Pharmingen 
anti-IA/IE FITC                    2G9                                        Rat (DA/HA) IgG2a, κ                      BD Pharmingen 
anti-IL-2 PE                          JES6-5H4                               RatIgG2b                                           BD Pharmingen 
anti-IL-12p40 PE                  C15.6                                     Rat IgG1                                            BD Pharmingen 
anti-TNF-α PE                      MP6-XT22                            RatIgG1                                             BD Pharmingen 
anti-IFN-γ PE                        XMG1.2                                RatIgG1                                             BD Pharmingen 
 
2.3.5. Buffers 
2.3.5.1. Erythrocyte or Red Blood Cell (RBC) Lysis Buffer (0.15 M) (100 ml) 
Constituent   Weight 
NH4Cl    829.0 mg 
KHCO3    100.0 mg 
Na2EDTA.2H2O      3.7 mg 
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2.3.5.2. Magnetic Cell Sorting (MACS) Buffers  
Running Buffer/MACS Buffer (500 ml) 
PBS    493.5 ml 
FCS (0.5%)       2.5 ml 
EDTA (2 mM)      4.0 ml from 250 mM stock solution 
Rinsing Solution (500 ml) 
PBS    496.0 ml 
EDTA (2 mM)      4.0 ml from 250 mM stock solution 
Cleaning Solution  
70% v/v ethanol 
2.3.5.3. Liberase Blendzyme Buffer (10 x) (100ml) 
 KCl    372.8 mg 
 CaCl2    266.0 mg  
 MgCl2      95.2 mg 
 NaCl        8.8 g 
 HEPES     10.0 ml from 1 M stock solution 
 
2.4. MACS Kits, Equipment and Accessories  
 
2.4.1. MACS Kits  
Basic MicroBeads                                      Miltenyi Biotec, Moenchengladbach, Germany 
CD11c (N418) MicroBeads                       Miltenyi Biotec 
Pan T cell isolation kit                     Miltenyi Biotec 
 
2.4.2. MACS Equipment and Consumables 
autoMACS Machine                                  Miltenyi Biotec 
autoMACS separator                                 Miltenyi Biotec 
MACS Pre-Separation Filters                    Miltenyi Biotec 
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2.5. Isolation of Organs and Fluids 
2.5.1. Blood 
The animals were sacrificed using CO2 and with the help of sterile forceps and scissors, the 
chest was cut open. From the opened rib cage, the heart was exposed and cut open. 
Thereafter, flowing blood was collected into 1.5 ml microcentrifuge tubes (Star Lab, 
Ahrensburg, Germany) using 1.0 ml pipette tip (shortened at the tip as to increase the area).  
The blood was kept at room temperature (RT) for 2 h for clotting. After that the blood was 
centrifuged at 9400 x g for 10 minutes at RT. After centrifugation, serum was collected and 
supernatant was further analyzed for various cytokines. 
 
2.5.2. Peritoneal lavage Fluid (PLF) 
The animals were sacrificed using CO2 and the peritoneal cavity of individual mouse was 
cannulated with a 20-gauge needle and 1 ml ice-cold PBS was injected and aspirated 
repeatedly with a syringe. This procedure was repeated two times. PLF was then 
centrifuged at 294 x g for 10 minutes at 4˚C. After centrifugation supernatant was collected 
and used to determine different cytokines by ELISA/CBA (as described in section 2.11.). 
 
2.5.3. Bone Marrow Cells (BMCs) Preparation  
The bone marrow cells were prepared from healthy control animals. The method described 
by Lutz et al. (Lutz et al., 1999), with minor modifications (as described in the following 
lines) was used. Animals were sacrificed using CO2 and the hind legs were isolated and 
femurs and tibias were cleanly excised and were freed from excess muscle tissue using 
sterile forceps and scissors and bones were kept in PBS on ice. After that bones were 
cleaned two times with 70% alcohol and two times with PBS successively. After that both 
ends of each femur and tibia were cut off and bone marrow was flushed out with a 27-
gauge needle (attached to a syringe with CM). Thereafter, BMCs were resuspended gently 
to dissolve cell aggregates and the cell suspension was transferred into 15 ml tubes and was 
centrifuged at 294 x g for 10 minutes at 4˚C. After centrifugation, the supernatant was 
discarded and the cell pellet was resuspended in 2 ml of CM. Cells were then counted and 
plated in 100 mm Petri dishes (BD Biosciences) at a concentration of 2 x 106 Cells/Petri 
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dish in 10 ml CM supplemented with 20 ng/ml rmGM-CSF (GM-CSF helps in the 
proliferation and differentiation of hematopoetic cells). On day 3, some Petri dishes with 
BMCs were used for the analysis of dendritic cell (DC) surface markers like CD11c and 
MHC II while rests of the Petri dishes were fed with culture medium containing 20 ng/ml 
rmGM-CSF. On day 7, non-adherent cells were harvested and counted. About 70-75% cells 
harvested on 7th day were MHC II and CD11c positive as confirmed by staining and FACS 
analyses (as described below). These cells are termed Bone Marrow derived Dendritic 
Cells (BMDCs) in the following. 
 
2.5.4. Total Spleen Cells Preparation 
The spleen was isolated separately from each animal and any extra tissue attached to it was 
carefully removed without cutting it. After that spleen was rinsed with 70% alcohol and 
500 µl of 0.02 U/ml Liberase Blendzyme 2 (Liberase Blendzyme is a mixture of highly 
purified collagenases and neutral protease enzymes, formulated for efficient and gentle 
dissociation of tissue. It acts on the collagen and non-collagen proteins that constitute the 
intercellular matrix) and was injected into the spleen with the help of a 27-gauge needle 
attached to a syringe. The spleen was then divided into three equal parts with the help of 
sterile scissors and kept in 15 ml of Liberase Blendzyme 2 solution at 37°C for 18 min. 
After treatment with Blendzyme, spleen was transferred to a 70 µm cell strainer (BD 
Biosciences) kept in the CM containing 5 mM EDTA and meshed gently. After that the 
cells were resuspended well and incubated for 5 min for dissociation of cell clusters. 
Thereafter, cells were passed through a 40 µm cell strainer (BD Biosciences) to remove any 
remaining tissue particle and collected in 50 ml tubes. After that the cells were centrifuged 
at 294 x g for 10 minutes at 4˚C. After centrifugation, the supernatant was removed and the 
cell pellet was resuspended in 1 ml erythrocyte lysis buffer. After that the cells were mixed 
gently and 6 ml CM was added quickly as to stop the lysis process. Thereafter, the cell 
suspension was underlaid with 1 ml of FCS (all the steps for RBC lysis were done at room 
temperature) and centrifuged at 294 x g for 10 minutes at 4˚C. After washing, cells were 
resuspended in 10 ml CM and counted.  
 
 24 
2.5.5. Total Lymph Node Cell Preparation 
The peripheral lymph nodes, inguinal and popliteal, were isolated and kept in CM on ice. 
The lymph nodes were transferred into Petri dish and each of them was flushed with CM 
using a 27-gauge needle. The remaining lymph node tissue was minced through a 40 µm 
cell strainer. Thereafter, cells were mixed gently and were incubated in CM containing 2 
mM EDTA in order to dissociate cell clusters. The cells were then collected in a 15 ml tube 
and centrifuged at 294 x g for 10 minutes at 4˚C. After washing, the supernatant was 
discarded and the cells were resuspended in 500 µl of CM and counted. 
 
2.6. Purification of Cells Using MACS Technology 
2.6.1. Principle and Method 
MACS is an extremely efficient magnetic separation technology using super-paramagnetic 
MicroBeads with surface antigen recognizing antibodies tagged to it.  
 
 
 
 
 
 
 
 
 
 
 
 
Using this technique, even the rarest cells can be isolated. The viability and purity of the 
separated cells is very high. MicroBeads are very small in size (about 50 nm in size) and 
Figure 6: The autoMACS™ separator from 
Miltenyi Biotech is an automated bench-top 
magnetic cell sorter. It is equipped with strong 
permanent magnets holding the separation columns 
and separates the magnetically labeled cells with 
high speed 
N S N S 
Figure 7: Magnetic cell separation using autoMACS. 
Labeled cells (shown in red) are retained in the 
column while unlabeled cells (shown in black) are 
collected as flow through. On further washing with 
MACS buffer and under controlled pressure, the 
retained fraction can be eluted. 
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are made up of iron oxide and polysaccharide. They are too small to be detected by optical 
methods. Therefore, they do not change the scatter properties of the cells during flow 
cytometer analysis. Moreover, selected cells can be used for culture as MicroBeads 
decompose during culture and do not change the cell viability and function. 
 
With MACS, cells of interest (positive selection) or cells to be depleted (negative selection) 
are specifically labeled with MicroBeads. After magnetic labeling, the cells are passed 
through a separation column which is placed in a strong permanent magnet. The 
magnetically labeled cells are retained in the column and separated from the unlabeled 
cells, which pass through. After washing the column with MACS buffer, the retained 
fraction can be eluted. Both fractions, labeled and unlabeled, are completely recovered.  
 
2.6.2. Usage 
2.6.2.1. Isolation of Splenic Dendritic Cells  
Splenic dendritic cells (DCs) were purified using CD11c MicroBeads according to the 
manufacturer’s recommendations. Total spleen cells without erythrocytes were 
magnetically labeled with CD11c MicroBeads and passed through a separation column 
placed in the magnetic field. The magnetically labeled CD11c+ cells were retained in the 
column and were collected as positive fraction. 
 
After preparation of TSCs (as described above with erythrocyte lysis step), cells were 
centrifuged at 294x g for 10 minutes at 4˚C, resuspended in CM and counted. After 
additional centrifugation, cells were resuspended in 500 µl of binding buffer (PBS + 0.5% 
FCS) per 108 total cells. Then 50 µl of 1:10 diluted Basic MicroBeads per 108 cells were 
added to the cell suspension. The cells were mixed with Basic MicroBeads for a few 
seconds and were washed with a 10-20 fold volume of binding buffer. After washing, the 
cells were resuspended in 500 µl of binding buffer per 108 cells and were loaded onto the 
autoMACS column to separate the viable cells without any non-specific material. The 
Basic MicroBeads treatment depletes material that binds non-specifically to MicroBeads 
like dead cells and debris. The effluent or unlabeled cells were collected and used further 
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for DCs isolation. After Basic MicroBeads step, the cells were counted and resuspended in 
400 µl of binding buffer per 108 total cells. Thereafter, 100 µl of CD11c MicroBeads per 
400 µl of cell suspension were added and cells were mixed gently and kept in dark at 4˚C. 
After 15 minutes, the cells were washed with binding buffer and centrifuged at 294 x g for 
10 minutes at 4˚C. After centrifugation, the cells were resuspended in 500 µl of binding 
buffer per 108 cells and were then loaded onto the autoMACS column to separate the 
CD11c labeled cells from unlabeled cells. The positive fraction (purified DCs) was 
collected, centrifuged, resuspended in 500 µl of CM and counted. The purity of DCs was 
generally 85-90% as confirmed by CD11c staining and FACS analysis.  
 
2.6.2.2. Isolation of total splenic T cells 
Total splenic T cells were isolated using Pan T cell isolation kit according to the 
manufacturer’s instructions. Using this kit, total mouse T cells were isolated by depletion of 
non-T cells like B cells, NK cells, dendritic cells, macrophages, granulocytes and erythroid 
cells which were indirectly labeled with a cocktail of biotin labeled monoclonal antibodies 
specific for their surface markers, as primary labeling reagent followed by anti-biotin 
monoclonal antibodies conjugated to MicroBeads, as secondary labeling reagent. Highly 
pure T cells were isolated by depletion of magnetically labeled non-T cells. 
 
After preparation of TSCs (as described above but without erythrocyte lysis step), cells 
were centrifuged at 294 x g for 10 minutes at 4˚C, resuspended in CM and counted. After 
centrifuging again, the cells were resuspended in 400 µl of binding buffer per 108 total 
cells. To 108 total cells, 100 µl of biotin labeled antibody cocktail was added, mixed well 
and kept for 10 minutes at 4˚C in dark. Thereafter, 300 µl of binding buffer and 200 µl of 
anti-biotin MicroBeads were added per 108 cells. The cells were mixed well and incubated 
for additional 15 minutes at 4˚C in the dark. The cells were washed and resuspended in 500 
µl of binding buffer per 108 cells and were then loaded onto the autoMACS column to 
separate the unlabeled cells from labeled cells. The negative fraction (purified total T cells) 
was collected, centrifuged, resuspended in 2 ml of CM and counted. The purity of T cells 
was generally more than 90% as confirmed by CD3 staining and FACS analysis. 
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2.7. Cell Culture 
2.7.1. Total Spleen Cells Culture 
The total spleen cells were cultured in CM in 96-well plates with or without 3 µg/ml Con A 
(Con A is a mitogen for T cells) or 5 ng/ml PMA + 500 ng/ml of Ionomycin (PMA 
activates Protein Kinase C and Ionomycin increases the concentration of calcium ions 
inside the cell and their combination brings about activation of T cells) for 2-3 days or in 
48-well plates, with or without 5 µg/ml CpG (CpG is a immunostimulatory molecule for 
antigen presenting cells like DCs) for 18 hours. After incubation, supernatants were 
collected for protein analysis (as described in section 2.11.) and nonadherent cells were 
used for FACS analysis. 
 
2.7.2. Splenic Dendritic Cells Culture 
The purified splenic DCs were cultured in CM containing 0.3 ng/ml rmGM-CSF in the 
absence or presence of 100 ng/ml LPS + 2.5 µg/ml CD40L (CD40L binds to CD40 and 
induces maturation and IL-12 release by DCs) or 5 µg/ml CpG (CpG induces IL-12 release 
by DCs) in 96-well flat-bottom plates (105 cells/well) for 18 h. In some experiments, 
stimulation of DCs was performed in the presence of rmIFN-γ (10 ng/ml) and in some other 
experiments neutralizing anti-IL-10 (αIL-10) antibodies (10 µg/ml) or the respective rat 
IgG1 isotype control (10 µg/ml). For the standardization of the amount of αIL-10 
antibodies needed to neutralize 1000 pg/ml IL-10 sufficiently, splenic DCs were purified 
from healthy control and cultured with or without CpG, in the absence or presence of 10 
µg/ml neutralizing αIL-10 antibodies in combination with 1 ng/ml or 5 ng/ml recombinant 
mouse IL-10 (rmIL-10) or 10 µg/ml of the rat IgG1 isotype control in combination with 1 
ng/ml or 5 ng/ml rmIL-10. The combination of αIL-10 and rmIL-10 or rat IgG1 isotype 
control + rmIL-10 was incubated for 30 minutes on ice prior to the addition to the cells. 
After addition of the mixture, cells were further incubated for 1 h and then CpG was added. 
After 18 h, supernatants were collected and were analyzed for IL-12 production. 
Experimental results have shown that 10 µg/ml αIL-10 antibodies were sufficient to 
neutralize the activity of 1000 pg/ml IL-10 and therefore, this concentration was used for 
the experiments. 
 28 
2.8. Flow Cytometry and Fluorescence Associated Cell analyses (FACS)  
2.8.1. Principle and Method 
Flow cytometry refers to the technique where measurements of the physical and chemical 
characteristics of the cells are made when they pass in a fluid stream through a measuring 
point surrounded by an array of detectors. At the measuring point in a typical flow 
cytometer the stream of cells intersects a beam of light from a laser (as shown in figure 8). 
When light interacts with biological particles some of the light is scattered out of the 
incident beam and this scattered light may be collected over a range of angles by detectors 
positioned around the measuring point. The light which is scattered in the forward 
direction, typically up to 20˚ offset from the laser beam’s axis, is collected by a detector 
known as the forward scatter channel (FSC). The FSC intensity roughly equates the 
particle’s size and can also be used to distinguish between cellular debris and living cells. 
The light which is measured approximately at a 90˚ angle to the excitation line is called 
side scatter. The side scatter channel (SSC) provides information about the granularity of 
the particle. Both FSC and SSC are specific for any particle, and the combination of both 
can be used to differentiate between different cell types in a heterogeneous sample. 
Additionally, fluorescence measurements taken at different wavelengths can provide 
quantitative and qualitative data about cell-surface or intracellular molecules which are 
labelled with different fluorochromes. The separate fluorescence (FL) channels are there in 
flow cytometers to detect emitted light (FL-1, FL-2 etc) (Fig. 8). The number of these FL 
channels varies from machine to machine and its manufacturer. In the present study 
FACScalibur (BD Biosciences) was used which is equipped with four FL channels. 
 
Fluorochromes used in the present study                       FL-channel 
FITC (Fluorescein isothiocyanate)      FL-1 
PE (Phycoerythrin)        FL-2 
PerCP-Cy5.5 (Peridinin-chorophyll-protein complex-cyanine 5.5)  FL-3 
APC (Allophycocyanin)       FL-4 
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In addition, the light may interact with the natural autofluorescent pigments present within 
the cell or with fluorescent stains added to the cells prior to analysis. In these cases cell-
associated fluorescence is also produced and these photons additionally may be collected 
by suitable detectors. The most important feature of flow cytometry is that it enables 
measurements to be made on individual cells at high speeds. This allows one to quantify the 
heterogeneity of the population of interest rather than merely to obtain average values for a 
population.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Schematic overview of a typical flow cytometer setup and the principle of flow cytometry.  
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2.8.2. Usage 
2.8.2.1. Surface Stainings 
For surface staining, cells (0.5-1x106) were washed with Cell Wash (BD). After 
centrifugation at 460 x g for 6 min at 4˚C, supernatant was discarded and cells were 
resuspended in 50 µl Cell Wash containing 1 µg Fc Block (BD) for blocking unspecific 
binding and kept at 4˚C in the dark. After 6 min, for the study of DCs surface and co-
stimulatory markers, 50 µl of antibody mixture containing anti-CD11c-APC in combination 
with anti-CD40-FITC (0.25 µg), anti-CD86-PE (0.005 µg), anti-CD80-FITC (0.5 µg), anti-
H2-Kd-PE (0.05 µg) anti-IAd-FITC (0.03 µg for non-stimulated cells staining and 0.015 µg 
for stimulated cells staining) , anti-CD8-FITC (0.125 µg), or anti-CD4-PE (0.8 µg) was 
added and cells were kept for additional 15 min. at 4˚C in the dark. After incubation in 
antibody mixture, 1 ml of Cell Wash was added and cells were centrifuged at 460 x g for 6 
minutes at 4˚C. After centrifugation, supernatant was discarded and cells were resuspended 
in 250 µl of Cell Wash for FACS analyses. 
 
In case of lymphocyte studies, for the detection of B cells anti-B220-FITC antibody (0.05 
µg) was used and for the T cell stimulation study, anti-CD3-FITC antibody (0.25 µg) in 
combination with anti-CD25-APC (0.05 µg) and anti-CD69-PE (0.1 µg) was used. The 
same staining process as described for the DCs was followed. 
 
The other cell types like monocytes and granulocytes were studied using anti-CD11b-
PerCP-Cy5.5 (0.2 µg) and anti-Gr-1-FITC (titrated amount of 0.5 µl) antibodies 
respectively. The same staining process as described for the DCs was followed. 
 
2.8.2.2. Intracellular Staining 
To measure stimulation-dependent changes in cytokine production on single-cell level, 
cells were stimulated with CpG (5 µg/ml) and during the last 4-6 h, monensin (GolgiStop 
0.66 µl/ml) was added. Monensin is an inhibitor of intracellular protein transport. This 
results in the accumulation of most cytokines inside the Golgi complex and thus enhances 
the detectability of cytokine-producing cells. After stimulation, cells were harvested and 
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centrifuged at 460x g for 6 minutes at 4˚C. After centrifugation, the supernatant was 
discarded and cells were resuspended in 50 µl Cell Wash containing 1 µg FcBlock (BD 
Biosciences) for blocking unspecific binding. After 6 min, cells were surface stained using 
anti-CD11c-APC or anti-CD4-FITC antibodies (as described above). The cells were then 
fixed and permeabilized using Cytofix/Cytoperm (it is used for simultaneous fixation and 
permeablization of the cells) for 20 min at RT. Thereafter, intracellular cytokines were 
stained using anti-IL-12p40-PE (0.4 µg), or anti-IL-2-PE (0.2 µg) antibodies. For analysis 
of IL-2 synthesis, co-cultures of splenic DCs and T cells were restimulated with 5 ng/ml 
PMA, 500 ng/ml ionomycin, and monensin (0.66 µl/ml) for 4 h before staining for 
intracellular IL-2. After washing with permeabilization buffer, cells were resuspended in 
Cell Wash and analyzed by FACS. 
 
Appropriate isotype controls were used for all stainings. All data were acquired using a 
FACScalibur (BD Biosciences) and analyzed using CellQuest pro software (BD 
Biosciences). For all stainings, the FL-3 channel was used to exclude autofluorescent cells. 
Living cells were selected according to forward and side scatter properties. The mean 
fluorescence intensity (MFI) (denotes the amount of marker or fluorochrome present on the 
surface of the cell population) of the respective molecules stained in combination with anti-
CD11c antibody was determined on gated, splenic CD11chi and lymph node CD11c+ DCs. 
Quadrant lines in dot plots were set as indicated in the figure legends. Total DC number per 
spleen was calculated as % CD11chi cells x total number of cells per spleen/100. 
 
2.9. Allogenic T cell Assay 
2.9.1. Carboxyfluorescein diacetate Succinimidyl Ester (CFDA-SE or 
CFSE) 
CFSE is used for labeling the cells. As the name suggests its chemical structure contains 
two acetate groups. It enters passively into the cells. It is colorless and nonfluorescent until 
its acetate groups are cleaved by intracellular esterases to give highly fluorescent, amine 
reactive carboxyfluorescein succinimidyl ester. The succinimidyl ester group reacts with 
intracellular amines, forming fluorescent complexes which are well retained inside the cell. 
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CFSE labeled cells induce a signal in the FL-1 channel and can be detected in 
flowcytometry (Fig. 9). 
 
 
 
 
 
 
 
 
 
 
 
Figure 9: The principle of CFSE staining 
 
2.9.2. CFSE Labeling of T cells 
Splenic CD3+ T cells from C57BL/6 or BALB/c mice were purified using Pan T Cell 
Isolation Kit (as described in section 2.7.2.2.). After isolation, T cells were stained with 
CFSE. After centrifugation at 294 x g for 10 minutes at 4˚C, the required number of T cells 
(4-8x106 in 500 µl) was resuspended in prewarmed PBS (1.5 µl microcentrifuge tubes were 
used). To the resuspended cells, 500 nM of CFSE (reconstituted in DMSO) was added and 
cells were gently resuspended and incubated for 12 minutes at 37˚C in a water bath. After 
incubation, cells were centrifuged and resuspended in 1 ml of prewarmed medium followed 
by incubation for 30 minutes at 37˚C in a water bath. After incubation, cells were 
centrifuged again at 294 x g for 10 minutes at 4˚C and resuspended in prewarmed medium. 
Cells were then counted and 2x105 T cells were added to the titrated amounts of purified 
splenic DCs (as described in section 2.9.3.). 
 
2.9.3. Splenic DCs and T cells Co-culture 
After labeling of T cells with CFSE, 2x105 T cells were added to the titrated amounts of 
purified splenic DC per well (96-well, half-area flat bottom plate, Corning, Germany). All 
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cultures were set up in triplicates. After 3 days, cells were harvested and cell clusters were 
dissociated through addition of 7.5 mM EDTA for 15 min. After washing with cell wash, T 
cells were stained using anti-CD3-PE antibody (0.4 µg). Labeled T cells were further mixed 
with 7-AAD (4 µg/ml) and a constant number of APC CaliBRITE APC beads (BD 
Biosciences). CaliBRITE APC beads were added in order to allow the acquisition of equal 
parts per culture. 7-AAD was used to exclude dead cells. For data acquisition, a constant 
number of CaliBRITE beads were counted. Living T cells (CD3+7-AAD-) were gated and 
the number of divided cells showing less than the maximal CFSE fluorescence intensity 
was determined. 
 
2.10. Transfer of Mature BMDCs into Septic Animals 
BMDCs were prepared as described above. On the 7th day, cells were harvested, 
centrifuged, resuspended in CM and counted. After counting, 2x106 cells were cultured in a 
total volume of 2 ml CM (supplemented with 10 ng/ml rmGM-CSF) in presence of 5 µg/ml 
CpG for 8 h in 6-well plates. After 8 h, non-adherent cells were harvested, washed twice 
with PBS and counted. The cells were then resuspended in PBS and each mouse was 
injected with 2x106 cells in 100 µl PBS intravenously (i.v.) or 100 µl PBS. 
 
2.11. Protein Analysis 
2.11.1. Enzyme Linked Immuno-Sorbent Assay  
2.11.1.1. Principle  
The enzyme linked immuno-sorbent assay (ELISA) is a protein assay in which bound 
antigen is detected by an antibody linked enzyme that converts a colorless substrate into a 
colored product. A modification of ELISA known as capture or sandwich ELISA is used in 
the present study to detect secreted products such as cytokines. In sandwich ELISA, 
cytokine-specific antibodies are bound to the plate, and thus bind cytokine molecules with 
high affinity even if cytokine molecules are present in very low concentrations. The 
separate biotinylated antibodies that recognize different epitopes in comparison to the 
immobilized first antibodies are then added to the bound cytokine molecules. Now, as to 
detect the sandwiched cytokine molecules, Horse Radish Peroxidase (HRP)-linked 
 34 
antibodies are added followed by the substrate which gives colored or fluorescent products. 
The spectroscopic measurement of the color intensity corresponds to the amount of 
cytokine present. 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Schematic graphic presentation of ELISA procedure 
 
Flow Diagram for ELISA Procedure 
 
96-well ELISA plate was coated with capture antibody and kept for overnight at RT or at 4˚C 
          Aspirated and washed 4x 
 
Incubated with blocking buffer for 1-2 hrs at RT 
          Aspirated and washed 4x 
Incubated with Standard/sample for 2 hrs at RT 
            Aspirated and washed 4x 
Incubated with detection antibody for 2 hrs at RT 
           Aspirated and washed 4x 
Incubated with HRP-linked biotinalated antibody for 20-30 min. at RT 
          Aspirated and washed 4x 
Incubated with substrate solution for 20-30 min. at RT 
 
Reading at 450/570 nm 
 
 
Incubation with capture 
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Aspirate and wash 4x 
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Measurement of the Amount of Cytokine 
The amount of cytokine present in the unknown sample was measured by preparing a 
standard curve. A standard curve was constructed by plotting varying amounts of known 
standard values and their corresponding optical densities (O.D.). The value of the unknown 
sample was then measured by comparing with the standard. A standard curve and unknown 
sample value was generated by using automated microplate reader (ELx 808, Bio-Tek 
instruments, Wilrijk, Belgium) and Mikro Win Version 3.0 software (Mikrotek, Overath, 
Germany). 
 
2.11.1.2. Usage in the Detection of Cytokines in Supernatants 
To measure stimulation-dependent changes in cytokine secretion, supernatants from 
stimulated TSCs cultures, purified splenic DCs cultures or from co-culture of splenic DCs 
and T cells were collected and tested for the production of IL-2, IL-10, IL-12, IFN-γ or 
TNF-α by ELISA as recommended by manufacturer’s (R&D systems, e-bioscience and 
Biosource, Solingen, Germany). 
 
2.11.2. BDTMCytometric Bead Array (CBA) 
2.11.2.1. Principle 
The BDTM CBA employs a series of particles (capture beads) with discrete fluorescence 
intensities to simultaneously detect multiple cytokines from single serum or cell culture 
supernatant sample. The CBA, combined with flow cytometry, creates a powerful multiple 
cytokine (multiplex) assay system. The CBA uses the sensitivity of amplified fluorescence 
detection by flow cytometry to measure cytokines with a particle-based immunoassay. The 
specific capture beads are mixed with recombinant protein standards or test samples then 
incubated with phycoerythrin (PE)-conjugated detection antibodies to form sandwich 
complexes.  
 
Following acquisition of sample data using the flow cytometer (BD FACScalibur), the 
sample results are generated using the new FCAP ArrayTM software (BD Biosciences). 
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Flow Diagram for CBA Procedure 
 
Incubation of capture beads (having distinct fluorescent intensities) with sample/standard for 1 h in 
dark at RT 
 
 
 
Incubation of capture beads plus sample/standard with PE-labeled detection antibodies for addition 
1 h in dark at RT 
                         Washed with 1 ml wash buffer 
 
 
Resuspension of sandwich complexes in 300 µl of buffer 
 
Acquisition and analysis of sample data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Schematic graphic representation of CBA technique (adapted from BD Biosciences website) 
Incubation of capture beads (having distinct 
fluorescent intensities) with sample/standard for 1 h 
Incubation of capture beads plus sample/standard with 
PE-labeled detection antibodies for 1 h 
Washing with 1 ml buffer 
Resuspension of sandwich complexes in 300 µl of buffer 
Acquisition and analysis of sample data 
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Measurement of the Amount of Cytokine 
The amount of various cytokines present in the unknown sample was determined by 
generating sample results in a graphical and tabular format using FCAP Array software. 
This software determines cytokine concentrations in the unknown sample based on known 
concentration values of a set of standards. It measures the MFI of the detector antibody 
(PE-labeled) for each cytokine. Thereafter, software fits a standard curve to the data from 
the concentration standards. The standard curve is used to calculate concentration values 
for each of the measured cytokine in each sample.  
 
2.11.2.2. Usage in the Detection of cytokines in Supernatants 
To measure stimulation-dependent changes in cytokine secretion, supernatants from 
stimulated TSCs cultures and purified splenic DCs cultures were tested for interleukin-12 
(IL-12), tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), interleukin-10 (IL-10),  
monocyte chemoattractant protein-1 (MCP-1) by using the cytometric bead array CBA 
Mouse Inflammation Kit. The supernatants from the co-culture of splenic DCs and T cells 
were tested for interleukin-2 (IL-2), TNF-α and IFN-γ using CBA Mouse Th1/Th2 Kit. 
 
2.12. Statistical Analyses 
Results are presented as the mean ± SD or mean ± SEM. Differences between sham and 
CLP groups were determined by paired Student’s t-test. The unpaired Student’s t-test was 
used to compare differences between replicates of cell cultures within one experiment. 
One-way analysis of variance (ANOVA) was determined for the differences between sham, 
CLP and CLP treated with CpG stimulated BMDCs. Post test analysis was performed with 
Tukey’s multiple range test. A P value < 0.05 was considered to be significant. 
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3. Results 
 
3.1. Characterization of Dendritic Cells during Sepsis 
3.1.1. Bacteria and Systemic Cytokines 
To characterize which bacteria or bacterial species were involved in the development of 
sepsis in the mouse after CLP, the gut exudate was analyzed using bacteriological methods. 
The analysis showed that Escherichia coli (Gram-negative), Bacillus species (mostly 
Gram-positive) and Lactobacillus species (Gram-positive) were present in the gut exudate.  
Next, to estimate how fast bacteria spread from the peritoneal cavity to the spleen which 
represents a systemic compartment, the total spleen cell suspensions were analyzed at 
different time-points following CLP or sham operation. Spleens were removed at 4, 8, 15 
and 36 h after operation and the total spleen cell suspensions were prepared and plated onto 
blood agar plates. Thereafter, plates were kept for overnight at 37˚C and were analyzed for 
the presence of bacterial colonies. In control animals for any given time points there were 
no colonies while bacterial colonies were formed as early as 4 h after CLP in septic animals 
(Table 2). 
 
 
 
 
Table 2: The presence of bacteria in spleen during sepsis. Four, 8, 15 and 36 h after CLP or sham operation, 
the total spleen cell suspensions were prepared and plated onto blood agar plates. After overnight incubation 
at 37˚C, plates were analyzed for the presence of bacterial colonies. (-) indicates no bacterial colonies and (+) 
indicates presence of bacterial colonies. 
 
After confirming the systemic presence of bacteria, the presence of different pro- and anti-
inflammatory cytokines in the blood was determined. Therefore, at 4, 8, 15 and 36 h after 
CLP or sham operation, blood was collected and serum was prepared and analyzed for 
TNF-α and IL-10. For all time points, septic mice showed increased serum levels of TNF-α 
and IL-10 as compared to control mice. Together, during polymicrobial sepsis the systemic 
spread of bacteria induces the activation of pro- and ant-inflammatory molecules.  
[h] 4 8 15 36 
Control - - - - 
CLP + + + + 
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3.1.2. Changes in Cell Number during Sepsis 
3.1.2.1. Change in Total Spleen Cells Number 
It is known that leukocytes undergo apoptosis during sepsis (Wesche et al., 2005). To 
investigate how total cell number of the spleen change in our CLP model, total spleen cell 
suspensions were prepared at different time-points following CLP or sham operation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: TSCs number during sepsis. Four, 8, 15 and 36 h after CLP or sham operation, TSCs from each 
animal were prepared and counted using trypan blue to exclude any dead cell. Data show dot plots where each 
dot show absolute number of total cells/spleen/animal (x 106) and are representative of two to six independent 
experiments per time point after CLP. 
 
Spleens were removed at 4, 15 and 36 h after operation and the total spleen cell suspensions 
were prepared and counted using trypan blue to exclude any dead cell. There was no 
change in cell number 4 h (Fig. 12A) and 8 h (Fig. 12B) after CLP while there was marked 
loss in total cell number 15 h (Fig. 12C) after CLP which gets further reduced 36 h (Fig. 
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12D) after CLP. Thus, in our sepsis model, the loss of total cell number in the spleen occurs 
between 8 and 15 h after CLP. 
 
3.1.2.2. Change in Dendritic Cells Number 
After looking at the loss in total spleen cell number during sepsis, next question concerning 
loss in splenic DCs number was addressed. Therefore, total spleen cells were prepared and 
stained for CD11c. DCs were identified according to their high expression of CD11c (Fig. 
13A and 13B). In control animals, 0.94 ± 0.15% of total spleen cells were DCs (Fig. 13C). 
         A 
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Figure 13: Total DCs number in the spleen. The total spleen cells were stained for CD11c. (A) CD11chi cells 
(DCs) were used for gating and analysis.  (B) CD11c and isotype control staining of total spleen cells. (C) 
Same histogram as in (B) but with enlarged scale of the y-axis in order to show the peak of unlabeled cells. 
Number indicates percentage of CD11chi cells. 
 
Further, the total number of DCs per spleen in CLP or sham operated mice was calculated. 
Spleens were removed at 8, 15 and 36 h after CLP or sham operation and stained for 
CD11c. The absolute number of DCs per spleen from septic and sham mice did not differ 
until 15 h after CLP. However, 36 h after CLP, the number of DCs in spleens from septic 
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mice decreased drastically down to 20% of DCs usually found in spleens from control mice 
(Fig. 14). Thus, polymicrobial sepsis induces profound loss of DCs in the spleen. 
 
 
 
 
 
 
 
 
 
 
Figure 14: Total DCs number in the spleen during sepsis. Eight, 15, and 36 h after CLP, total spleen cells per 
group (n=3 to 4) were pooled and stained for CD11c. Sham operation served as control. The total numbers of 
DCs per spleen of control (open bars) and septic mice (filled bars) were calculated. Data show mean ± SD of 
3 to 4 experiments per time point. Asterisk indicates significant difference between CLP and control groups. 
*, p<0.05 
 
3.1.3. Specific Loss of DCs Subpopulations in the Spleen during Sepsis  
On the basis of their expression of CD4 and the CD8α chain homodimer (CD8αα), splenic 
DCs can be further segregated into three subtypes (CD4+CD8-, CD4-CD8+, CD4-CD8-). As 
shown in section 3.1.2.2., 80% of splenic DCs were lost during sepsis. Thus, we addressed 
the question of whether all DC subpopulations were affected or whether there was a 
prevalence of a specific DCs subpopulation. Therefore, total spleen cells were prepared 8 
and 36 h after CLP or sham operation and the distribution of DC on the three main 
subpopulations in the spleen was determined. DCs from control mice mainly belonged to 
the CD4+CD8- subpopulation (72%), remaining cells were found in the CD4-CD8+ (11%) 
and the CD4-CD8- (15%) subsets (Fig. 15A). However, the distribution of DCs from septic 
mice 36 h after CLP completely differed from this pattern as shown by clearly decreased 
CD4+CD8- (49%) and CD4-CD8+ (2%) subpopulations but an increased CD4-CD8- 
subpopulation (47%, Fig. 15A). Comparison of the absolute numbers of the three DC 
subtypes per spleen demonstrated that by 8 h after CLP the size of the three subpopulations 
did not differ between DCs from control and DCs from septic mice. However, by 36 h after 
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CLP a profound loss of CD4+CD8- and of CD4-CD8+ DCs was observed. The number of 
CD4-CD8- DCs did not change significantly (Fig. 15B). Thus, the loss of splenic DCs 
during sepsis can be attributed to a selective depletion of two specific DC subsets. 
                                                 B 
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Figure 15: DC subpopulations during sepsis. Eight and 36 h after CLP or sham operation, pooled spleen cells 
(n=3 to 4 per group) were stained for CD11c, CD4, and CD8. (A) Expression of CD4 and CD8 on CD11chi 
DC 36 h after operation. Numbers indicate percentage of cells in the respective quadrant. Data are 
representative for 4 experiments. (B) Absolute numbers of DCs per spleen belonging to the three 
subpopulations 8 and 36 h after operation. Data show mean ± SD of 2 (for 8 h) and 4 (for 36 h) experiments. 
Asterisks indicate differences between CLP (filled bars) and control groups (white bars). **, p<0.01. 
 
3.1.4. Maturation of DCs in the Spleen and in the Peripheral Lymph 
Nodes during Sepsis 
3.1.4.1. Rapid Maturation of DCs in the Spleen 
To test whether sepsis is associated with a change in the expression of surface markers 
involved in T cell activation on splenic DCs (CD11chi), total spleen cell suspensions were 
prepared at different time-points following CLP or sham operation. Spleens were removed 
at 4, 8, 15 and 36 h after operation and were stained for CD11c in combination with CD40, 
CD80, CD86, MHC class I and MHC class II.  
 
At 4 h after CLP, DCs from septic mice expressed similar levels of CD40 and slightly 
enhanced levels of CD86 in comparison with DCs from control mice (Fig. 16). However, at 
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36 h after CLP, the expression of CD40 and CD86 was strongly enhanced, clearly 
indicating sepsis-induced maturation (Fig. 16). 
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Figure 16: Maturation of splenic DCs during sepsis. Four and 36 h after CLP or sham operation, total spleen 
cells per group (n=3-4) were pooled and stained for CD11c in combination with CD40 and CD86. Data show 
CD40 and CD86 expression of DCs 4 and 36 h after CLP or sham operation and are representative of four 
independent experiments. Quadrant lines were set where isotype controls showed less than 2% false positive 
cells. 
 
The kinetics showed that CD86 was upregulated further at 8 h after CLP and reached 
maximal expression at 15 h after CLP (Fig. 17B). 
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Figure 17: Maturation of splenic DCs during sepsis. Eight, 15 and 36 h after CLP or sham operation, total 
spleen cells per group (n=3-4) were pooled and stained for CD11c in combination with CD86. (A) Data show 
CD86 expression of DCs 8 h after CLP or sham operation. These data represent dot plots for any other time 
points after CLP. Quadrant lines were set where isotype controls showed less than 2% false positive cells. (B) 
MFI values of the indicated surface markers on DCs (gated on CD11chi, as shown in fig. 13A) were 
determined. The ratio of MFI values of DCs from septic (filled bars) versus control (open bars) mice was 
calculated for variations between different experiments. Data show mean ± SD of two (for 8 and 15 h) or four 
(for 36 h) independent experiments.  
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Further, increased expression of CD40 was visible at 15 h after CLP, which reached its 
maximum at 36 h after CLP (Fig. 18B). 
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Figure 18: Maturation of splenic DCs during sepsis. Eight, 15 and 36 h after CLP or sham operation, total 
spleen cells per group (n=3-4) were pooled and stained for CD11c in combination with CD40. (A) Data show 
CD40 expression of DCs 8 h after CLP or sham operation. These data represent dot plots for any other time 
points after CLP. Quadrant lines were set where isotype controls showed less than 2% false positive cells. (B) 
MFI values of the indicated surface markers on DCs (gated on CD11chi, as shown in fig. 13A) were 
determined. The ratio of MFI values of DCs from septic (filled bars) versus control (open bars) mice was 
calculated for variations between different experiments. Data show mean ± SD of two (for 8 and 15 h) or four 
(for 36 h) independent experiments. 
 
 
MHC class I expression followed a remarkable kinetics, as it remained unaffected during 
the first 15 h after CLP but enhanced strongly at 36 h after CLP (Fig. 19B).  
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Figure 19: Maturation of splenic DCs during sepsis. Eight, 15 and 36 h after CLP or sham operation, total 
spleen cells per group (n=3-4) were pooled and stained for CD11c in combination with MHC class I. (A) Data 
show MHC class I expression of DCs 8 h after CLP or sham operation. These data represent dot plots for any 
other time points after CLP. Quadrant lines were set where isotype controls showed less than 2% false 
positive cells. (B) MFI values of the indicated surface markers on DCs (gated on CD11chi, as shown in fig. 
13A) were determined. The ratio of MFI values of DCs from septic (filled bars) versus control (open bars) 
mice was calculated for variations between different experiments. Data show mean ± SD of two (for 8 and 15 
h) or four (for 36 h) independent experiments. 
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In contrast, sepsis induced moderate or no changes in the expression of CD80 and MHC 
class II molecules on splenic DCs (Fig. 20B). Thus, polymicrobial sepsis strongly induces 
maturation of DCs in the spleen. 
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Figure 20: Maturation of splenic DCs during sepsis. Eight, 15 and 36 h after CLP or sham operation, total 
spleen cells per group (n=3-4) were pooled and stained for CD11c in combination with CD80 and MHC class 
II. (A) Data show CD80 and MHC class II expression of DCs 8 h after CLP or sham operation. These data 
represent dot plots for any other time points after CLP. Quadrant lines were set where isotype controls 
showed less than 2% false positive cells. (B) MFI values of the indicated surface markers on DCs (gated on 
CD11chi, as shown in fig. 13A) were determined. The ratio of MFI values of DCs from septic (filled bars) 
versus control (open bars) mice was calculated for variations between different experiments. Data show mean 
± SD of two (for 8 and 15 h) or four (for 36 h) independent experiments. 
 
3.1.4.2. Maturation of DCs in the Peripheral Lymph Nodes 
Further, to test whether the sepsis-associated maturation was restricted to DCs in the 
spleen, the expression of surface markers on CD11c+ DCs from inguinal and popliteal 
peripheral lymph nodes, as lymphoid organs distant to the site of infection, was determined 
at various time points. At 8 h after CLP, CD86, CD40 and MHC class II were expressed at 
the same levels as found on DCs from controls (Fig. 21). While 15 h after CLP, CD40 and 
CD86 were increased slightly on DCs from septic mice (Fig. 21). Moreover, 36 h after 
CLP, lymph node DCs from septic mice upregulated all surface molecules including CD80 
and MHC class II, which were only marginally changed on splenic DCs (Fig. 21). MHC 
class I expression was also enhanced 36 h after CLP as compared to controls (Fig. 21). 
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Thus, sepsis-induced maturation of DCs in the lymph nodes resembles the maturation of 
splenic DCs but is characterized by slightly delayed kinetics and followed a different 
pattern of surface markers upregulation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Maturation of peripheral lymph node DC during sepsis. Eight, 15, and 36 h after CLP or sham 
operation, pooled popliteal and inguinal lymph node cells (n=3 to 4 per group) were stained. CD11c+ DC 
were gated and MFI values for the indicated surface markers were determined. The ratio of MFI values from 
DC from septic (hatched bars) versus control (white bars) mice were calculated. Data show mean ± SD of 2 to 
4 independent experiments per time point. n.d., not determined 
 
3.1.5. Altered Cytokine Secretion Pattern of DCs during Sepsis 
3.1.5.1. Impaired Pro-inflammatory Cytokine Response, but Release of IL-10 by DCs 
during Sepsis 
It is known that containment of an infection induces DCs maturation and release of various 
pro-inflammatory cytokines like TNF-α, IFN-γ and IL-12 and anti- inflammatory cytokines 
like IL-10. IL-12 is a key mediator for Th1 cell polarization while its counterpart IL-10 is a 
major anti-inflammatory cytokine and induces an immunoregulatory response. The 
effective clearance of bacterial infection requires the development of Th1 cell response. 
Therefore, the question related to their capacity to produce TNF-α, IFN-γ, IL-12 and IL-10 
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was addressed. At 8, 15 and 36 h after CLP and sham operation, DCs were purified from 
the total spleen cells and were cultured with or without CD40 Ligand+LPS (CD40L+L) or 
immunostimulatory CpG oligonucleotides. After 18 h of culture, supernatants were 
analyzed for the presence of TNF-α and IFN-γ. The results showed that DCs from control 
mice secreted substantial amounts of TNF-α and IFN-γ upon stimulation with CpG or 
CD40L+LPS. However, the secretions of these pro-inflammatory cytokines by DCs from 
septic mice were reduced by more than 50 % as soon as 8 h after CLP and were further 
reduced up to 36 h after CLP (Fig. 22). 
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Figure 22: Synthesis of TNF-α and IFN-γ in response to bacterial components. Eight, 15, and 36 h after CLP 
or sham operation, spleen cells were pooled (n=3 to 4 per group) and DCs were purified and cultured in the 
presence or absence of 100 ng/ml LPS + 2.5 µg/ml CD40L (CD40L+L) or with 5 µg/ml CpG for 18 h. 
Supernatants of DCs from septic mice and from control mice were analyzed for TNF-α and IFN-γ. Data show 
mean ± SD and are representative for 2 experiments per time point. n.d., not determined. 
 
 
Next, the capacity of DCs to produce IL-12 was analyzed. IL-12 is a heterodimeric pro-
inflammatory cytokine comprising of covalently linked p40 and p35 subunit. At 36 h after 
CLP or sham operation, the total spleen cells were cultured with or without 
immunostimulatory CpG oligonucleotides. Thereafter, intracellular staining for IL-12p40 
was done with total spleen cells in combination with anti-CD11c. Intracellular expression 
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of IL-12p40 on CD11chi gated DCs were determined using FACS analysis. The results 
showed that only very few DCs from control and septic mice produced IL-12p40 in the 
absence of CpG stimulation while about 33% DCs from control mice produced IL-12p40 as 
compared to septic DCs in the presence of CpG stimulation (Fig. 23). Only 6% of DCs 
from septic mice were able to produce IL-12p40 in the presence of CpG stimulation (Fig. 
23).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: Synthesis of IL-12p40 in response to bacterial components. Thirty-six hours after CLP or sham 
operation, spleen cells were pooled (n=3 to 4 per group). Thereafter, total spleen cells were cultured with or 
without 5 µg/ml CpG for 18 h and monensin was added for further 6 h. After surface staining of CD11c, cells 
were fixed, permeabilized, and stained for intracellular IL-12p40. CD11chi cells were gated. Quadrant lines 
were set where isotype control antibodies stained less than 1% of the cells. Numbers indicate percentage of 
IL-12p40 positive cells. Data are representative of three independent experiments. 
 
In addition, DCs purified from total spleen cells were analyzed for IL-12p70 (bio-active 
form of IL-12) and IL-10 in the culture supernatants. Therefore, to check their presence, 
DCs from the total spleen cells were purified at 4, 8 and 36 h after CLP or sham operation 
and were stimulated with CD40L+LPS or with CpG. After 18 h, supernatants were 
analyzed for IL-12 and IL-10. At any time-point, supernatants from unstimulated DCs from 
sham as well as from septic mice showed only low levels of IL-12. DCs from control mice 
secreted IL-12 in response to CD40L+LPS or CpG but produced only low amounts of IL-
10 (Fig. 24). Four hours after CLP, DCs from septic mice showed the same capacity to 
release IL-12 and IL-10 upon stimulation with CpG as DCs from control mice. However, at 
8 and 36 h after CLP, DCs from septic mice secreted only minute amounts of IL-12 upon 
stimulation with CD40L+LPS or CpG, and the capacity of control DCs to secrete IL-12 
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remained stable. In contrast, DCs from septic mice released increasing amount of IL-10 
even in the absence of any additional stimuli up to 36 h after CLP (Fig. 24). Thus, during 
polymicrobial sepsis DCs develop an inverse cytokine secretion pattern in response to 
bacterial stimuli associated with a predominance of IL-10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.1.5.2. Endogenous IL-10 is not responsible for Suppressed IL-12 Synthesis by 
Splenic DCs from Septic Mice  
It has been reported that endogenous IL-10 in DCs acts in an autocrine manner and 
regulates IL-12 synthesis by DCs (Corinti et al., 2001). Thus, the next question regarding 
putative role of endogenous IL-10 in impaired IL-12 synthesis from DCs during sepsis was 
asked. The IL-10 neutralizing experiment with the help of anti-IL-10 (αIL-10) antibodies or 
respective isotype controls was performed. First, the standardization for the amounts of 
anti-IL-10 antibodies and respective isotype control was made. Second, the effect of IL-10 
neutralization on IL-12 release by DCs during sepsis was investigated. Therefore, splenic 
DCs were purified from healthy control and cultured with or without CpG, in the absence 
or presence of 10 µg/ml neutralizing αIL-10 antibodies in combination with 1 ng/ml or 5 
Figure 24: Synthesis of IL-12 and IL-
10 in response to bacterial 
components. Four, 8, and 36 h after 
CLP or sham operation, spleen cells 
were pooled (n=3 to 4 per group). 
Four, 8, and 36 h after operation, DCs 
were purified from total spleen cells 
and cultured in the presence or 
absence of 100 ng/ml LPS + 2.5 µg/ml 
CD40L or with 5 µg/ml CpG for 18 h. 
Supernatants of DCs from septic mice 
(filled bars) and from control mice 
(white bars) were analyzed for IL-
12p70 and IL-10. Data show mean ± 
SEM of triplicate cultures and are 
representative for 2 experiments per 
time point. n.d., not determined. 
Asterisks indicate significant 
differences between cultures of sham 
and CLP groups. *, p<0.05; **, 
p<0.01; ***, p<0.0005. 
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ng/ml recombinant mouse IL-10 (rmIL-10) or 10 µg/ml of the rat IgG1 isotype control in 
combination with 1 ng/ml or 5 ng/ml rmIL-10 (Fig. 25). After 18 h, supernatants were 
analyzed for IL-12 production. The results showed that 10 µg/ml of αIL-10 antibodies were 
able to neutralize 1000 pg/ml of IL-10 efficiently (Fig. 25).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Next, for the second part, splenic DCs were purified 24 h after CLP or sham operation and 
stimulated with or without CpG in the presence or absence of neutralizing αIL-10 
antibodies or the respective isotype control. After 18 h, supernatants were tested for IL-12. 
In response to CpG, DCs from sham mice released high levels of IL-12 that were further 
increased in the presence of αIL-10 antibodies but not in the presence of the isotype control 
antibodies (Fig. 26). However, CpG-stimulated DCs from septic mice did not release IL-12 
in the absence or in the presence of anti-IL-10 or isotype control antibodies (Fig. 26).  
 
 
 
 
 
 
 
 
Figure 26: Effect of endogenous IL-10 on IL-12 
synthesis. Splenic DCs were purified 24 h after CLP or 
sham operation and cultured with or without 5 µg/ml 
CpG each in the absence or presence of 10 µg/ml 
neutralizing anti-IL-10 (αIL-10) antibodies or 10 µg/ml 
of the rat IgG1 isotype control for 18 h. Supernatants of 
DCs from sham mice and septic mice were tested for IL-
12. Data show mean ± SEM of triplicate cultures and are 
representative for 2 experiments. Asterisks indicate 
significant difference between anti-IL-10 and isotype 
control-treated cultures. ***, p<0.0001 
Figure 25: Amount of anti-IL-10 (αIL-10) 
antibodies needed for sufficient 
neutralization of 1000 pg/ml of IL-10. 
Splenic DCs were purified from healthy 
controls and cultured with or without 5 
µg/ml of CpG, in the absence or presence 
of 10 µg/ml neutralizing αIL-10 antibodies 
or 10 µg/ml of the rat IgG1 isotype control 
in combination with 1 ng/ml or 5 ng/ml 
recombinant mouse IL-10 (rmIL-10) for 18 
h. Supernatants of DCs were tested for IL-
12. Data show mean ± SD of quadruplicate 
cultures.  
 
 51 
3.1.5.3. Exogenous Treatment with IFN-γ Increases IL-12 Production by Splenic DCs 
from Septic Mice during Early Sepsis 
DCs-derived IL-10 was not responsible for suppressed IL-12 production during sepsis, as 
neutralization of IL-10 did not restore IL-12 production by splenic DCs from septic mice 
(section 3.1.5.2.). Thus, the question regarding the role of another cytokine like IFN-γ in 
IL-12 production by DCs was asked. IFN-γ is known to promote IL-12 release by DCs 
(Snijders et al., 1998). Therefore, DCs from the total spleen cells were purified at 3, 6 and 
24 h after CLP or sham operation and were stimulated with or without CpG in the absence 
or presence of recombinant mouse IFN-γ (rmIFN-γ) for 18 h. Supernatants were analyzed 
for IL-12. At any time point, supernatants from unstimulated DCs from sham as well as 
from septic mice contained only low levels of IL-12. Further, at any time point, in response 
to CpG, DCs from sham mice released high levels of IL-12, which were increased further 
in the presence of IFN-γ (Fig. 27). However, CpG-stimulated DCs from septic mice 
released lower levels of IL-12 as compared to control mice at 3 and 6 h after CLP and this 
release of IL-12 were further decreased at 24 h after CLP (Fig. 27). Upon IFN-γ treatment, 
DCs from septic mice released slightly increased levels of IL-12 at 3 h after CLP but this 
increased release of IL-12 on IFN-γ treatment was absent at 6 and 24 h after CLP (Fig. 27). 
Taken together, exogenous IFN-γ treatment partially restores IL-12 production by DCs 
upon CpG stimulation during early hours of sepsis, but it doesn’t function in restoring IL-
12 synthesis at later times. 
 
 
 
 
 
 
 
 
 
 
Figure 27: Exogenous treatment with rmIFN-γ increases IL-12 production by DCs from septic mice. Three, 6 
and 24 h after CLP or sham operation, splenic DCs were purified and cultured with or without 5 µg/ml CpG 
and in the absence or presence of 10 ng/ml rmIFN-γ for 18 h. Supernatants of DCs from sham mice and septic 
mice were tested for IL-12. Data show mean ± SD of triplicate cultures. 
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3.1.6. Release of the Chemokine MCP-1 by DCs during Late Sepsis 
Besides producing various pro- and anti-inflammatory cytokines, DCs also represent an 
important source of chemokines in vitro and in vivo. Production of chemokines is strongly 
increased during maturation of DCs. Mature DCs produce conspicuous amounts of various 
chemokines like CCL2 (MCP-1), CCL3 (MIP-1α) etc. Therefore, the capacity of DCs to 
produce MCP-1 during sepsis was addressed. At 8, 15 and 36 h after CLP and sham 
operation, DCs were purified from the total spleen cells and were cultured with or without 
CD40 Ligand + LPS (CD40L+L) or immunostimulatory CpG oligonucleotides. After 18 h 
of culture, supernatants were analyzed for MCP-1. The results showed that DCs from 
control mice could not be stimulated for MCP-1 release at any time point (Fig. 28). In 
contrast, 40 h after sepsis, DCs from septic mice showed spontaneous release of MCP-1. 
This suggested the in vivo release of MCP-1 by DCs that was reduced upon further 
stimulations (Fig. 28). 
 
 
 
 
 
 
 
 
 
 
 
Figure 28: Synthesis of MCP-1 in response to bacterial components. Eight, 15 and 36 h after CLP or sham 
operation, spleen cells were pooled (n=3 to 4 per group) and DCs were purified and cultured in the presence 
or absence of 100 ng/ml LPS + 2.5 µg/ml CD40L (CD40L+L) or with 5 µg/ml CpG for 18 h. Supernatants 
from septic mice and from control mice were analyzed for MCP-1. Data show mean ± SD. 
 
3.1.7. Reduced T Cell-Stimulatory Capacity of DCs during Sepsis 
DCs are known potent antigen presenting cells which capture foreign antigen, process and 
present it to the T cells and in turn activate them. Therefore, the capacity of splenic DCs to 
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induce T cell activation was addressed. Splenic DCs were purified 36 h after CLP or sham 
operation and cultured with allogeneic T cells (T cells from C57BL/6J mice). DCs from 
septic mice were less potent in inducing T cell proliferation than DCs from control mice 
(Fig. 29). IL-2 is crucial for T cell proliferation and it acts in an autocrine manner. 
Therefore, the capacity of T cells to produce IL-2 in DC/T cell cocultures was addressed. 
At 36 h after CLP, CD4+ T cells from mixed lymphocyte cocultures were analyzed for their 
ability to produce IL-2 upon restimulation with PMA/Ionomycin. The percentage of IL-2-
secreting T cells cultured with DCs from septic mice was decreased by more than two-fold 
in comparison to T cells cultured with DCs from control mice (Fig. 30). Taken together, 
although expressing high levels of costimulatory molecules, DCs from septic mice were 
less potent in T cell activation than DCs from control mice. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: Proliferation test in allogeneic T cell assay. 
Thirty-Six hours after CLP or sham operation, DCs were 
purified from pooled spleen cells (n=3 to 4 per group). 
Titrated numbers of DCs were seeded in 96-well plates and 
cultured for 18 h. CFSE-labeled allogeneic T cells were 
added and proliferation was determined after 3 d as 
described in Material and Methods. Data show mean ± 
SEM of triplicate cultures with DCs from controls (white 
squares) and from septic mice (black squares). 
Figure 30: IL-2 synthesis in allogeneic T cell assay. 
Thirty-six h after CLP or sham operation, DCs were 
purified from pooled spleen cells (n=3 to 4 per 
group). Titrated numbers of DCs were seeded in 96-
well plates and cultured for 18 h. The unlabeled 
allogeneic T cells were added to 104 DCs. After 4 d, 
cells were restimulated with PMA/Ionomycin 
before staining for CD4 and intracellular IL-2. 
CD4+ cells were gated. Numbers indicate 
percentage of cells positive for IL-2. Isotype control 
antibodies stained less than 1%. Data are 
representative for 2 experiments. 
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3.2. Restoration of Dendritic Cell Functions during Sepsis 
In the present study, the changes in the behavior of DCs was investigated during sepsis and 
found that there was a significant increase in DC IL-10 release and a significant decrease in 
DC IL-12 release when compared with controls. This would change the DCs Th 
polarization properties, yielding a phenotype more likely to promote the development of a 
Th2 or Treg lymphocyte response. There was also a marked loss in DC number and the 
remaining DCs showed a reduced ability to drive clonal expansion of T cells in a mixed 
lymphocyte reaction. From the data collected, it was clear that DCs were affected by 
environmental factors seen in sepsis. By keeping this information in mind, studies on the 
development of potential strategy for the restoration of DC functions was aimed.  
 
3.2.1. Strategy Followed for Restoration 
DCs play a pivotal role in the establishment of a specific immune response against 
pathogens and an alteration in DCs function may have accounted for the 
immunosuppression during sepsis. Treatment strategy which could restore the capacity of 
DCs for Th1 cell polarization or the normal DCs count seem to represent promising 
approach to counteract immunoparalysis during sepsis. To address this question, the 
transfer of ex vivo generated Bone Marrow-derived Dendritic Cells (BMDCs) from naïve 
animals into CLP treated animals was attempted. 
 
3.2.2. Experimental Plan 
3.2.2.1. Isolation of Mouse BMDCs 
The BMDCs were generated by performing the following steps (details are in materials and 
methods section) and were further used for transfer into CLP-treated mice. 
 
 
 
 
 
 
Figure 31: Schematic presentation for BMDCs generation for injection. 
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3.2.2.2. Transfer of BMDCs 
Six hours after sham and CLP operation, mice were injected with BMDCs or PBS (Fig. 32). 
The CLP treated mice were divided into three groups. First group was injected with PBS 
(100 µl/animal) intravenously (i.v.). While second and third groups of CLP treated mice 
were injected with CpG treated wildtype BMDCs and with CpG treated IL-12p35-/- (IL-12-
KO) BMDCs (2 x 106 cells/100 µl/animal) i.v., respectively. IL-12KO BMDCs were 
injected to analyze the role of IL-12, which is required for Th1-type cell response during 
sepsis. And sham treated mice were injected with PBS (100 µl/animal) i.v. only. The 
experimental plan followed for injection is shown as below 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32: Schematic presentation for BMDCs transfer. 
 
3.2.3. Characterization of BMDCs from Naïve Animal 
Prior to transfer experiments, the characterization of BMDCs was done on the basis of 
various parameters like expression of surface markers involved in T cell activation (MHC 
class II molecules) and IL-12 release in response to bacterial products like CpG. The 
cultured bone marrow cells (BMCs) were harvested on 7th day (as described in materials 
and methods) and stained for CD11c in combination with MHC class II. BMDCs were 
identified according to their expression of CD11c and MHC class II (Fig. 33B). About 70-
75% BMCs harvested on 7th day were CD11c and MHC II positive (Fig. 33B) and were 
termed BMDCs. 
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Figure 33: Total number of BMDCs in BMCs preparation on 7th day. BMCs were stained for CD11c and 
MHC class II (A) Total CD11c cells in BMCs preparation. Number indicates percentage of CD11c cells. (B) 
Total CD11c cells were gated and analyzed for MHC class II. BMDCs were positive for CD11c and MHC 
class II. Number indicates percentage of BMDCs. 
 
In addition to surface molecules analysis, BMDCs were analyzed for IL-12 production. On 
the 7th day, harvested BMDCs were cultured with or without CpG for 18 h. Thereafter, 
supernatants were tested for IL-12. The results showed that BMDCs in presence of CpG 
produced high levels of IL-12 (Fig. 34). Together, BMDCs used for therapy expressed high 
levels of MHC class II molecules and released high amounts of IL-12 upon CpG 
stimulation. 
 
 
 
 
 
 
 
 
 
3.2.4. BMDCs Transfer Reduces Cell Loss during Sepsis  
3.2.4.1. Reduction in Total Spleen Cells Loss 
To get insight into the effects of BMDCs transfer during sepsis on the total number of 
spleen cells (TSCs) in our CLP model, total spleen cell suspensions were prepared at 24 h 
after CLP or sham operation. The cells were counted and total number of cells per spleen 
70 CD11c 
Figure 34: Synthesis of IL-12 in 
response to CpG. On 7th day 
BMDCs were cultured with or 
without 5 µg/ml CpG for 18 h. 
Supernatants were then analyzed 
for IL-12p70 production. Data 
show mean ± SD of triplicate 
cultures. 
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was calculated. The total number of cells in spleens from septic mice injected with PBS 
[CLP (P)] declined down to 60 % of total cells usually found in spleens from control mice 
injected with PBS [Control (P)]. This 40% loss in cell number was partially restored in 
spleens from septic mice injected with CpG oligonucleotides stimulated wildtype BMDCs 
[CLP (B+C)] (Fig. 35). Thus, during polymicrobial sepsis transfer of BMDCs in CLP 
treated mice reduces in part the loss in total cell number in the spleen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.4.2. Reduction in Total T cells Loss 
After looking at the reduction in loss of total spleen cells on BMDCs transfer during sepsis, 
next question concerning total T cell number in spleen was addressed. According to their 
expression of CD4 and CD8, two T cell populations can be distinguished in the spleen.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35: Total cell number in the spleen on 
BMDCs transfer during sepsis. Twenty-four 
hours after CLP or sham operation, the total 
numbers of cell per spleen of control mice 
injected with PBS (open bar), septic mice 
injected with PBS (black bar) and septic mice 
injected with CpG oligonucleotdes treated 
wildtype BMDCs (gray bar) were calculated. 
Data show mean ± SD of seven independent 
experiments. ***, indicates significant 
difference between sham and CLP groups, 
p<0.0005; and *, indicates significant 
difference between CLP and BMDCs treated 
CLP groups, p<0.05.   
Figure 36: Total T cell number in the 
spleen on BMDCs transfer during sepsis. 
Twenty-four hours after CLP or sham 
operation, the total spleen cells from 
each animal from each group were 
stained for CD4 and CD8. These data 
show the sum of absolute numbers of 
CD4 and CD8 cells per spleen which 
represents the total T cell number per 
spleen of septic mice injected with PBS 
(black bar) and septic mice injected with 
CpG oligonucleotides treated wildtype 
BMDCs (gray bar). Data show mean ± 
SD of four independent experiments. *, 
indicates significant difference between 
CLP and BMDCs treated CLP groups, 
p<0.05. 
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Total spleen cell suspensions were prepared at 24 h after CLP or sham operation and were 
stained for CD4 and CD8, counted and the absolute number of CD4 and CD8 T cells per 
spleen was calculated. Thereafter, to determine the change in the total T cells number, 
absolute numbers of CD4 and CD8 T cells were summed up. The total number of T cells in 
spleens from septic mice injected with PBS [CLP (P)] declined down to 60 % of total T 
cells usually found in spleens from control mice injected with PBS [Control (P)]. This 40% 
loss in T cell number was partially restored in spleens from septic mice injected with CpG 
oligonucleotides stimulated wildtype BMDCs [CLP (B+C)] (Fig. 36). Thus, during 
polymicrobial sepsis transfer of BMDCs in CLP treated mice reduces in part the loss in 
total T cell number in the spleen. 
 
3.2.5. Altered Cytokine Secretion Pattern of Total Spleen Cells during 
Sepsis  
Next, the capacity of TSCs to produce pro- and anti-inflammatory cytokines was analyzed. 
Therefore, the release of TNF-α, IFN-γ and IL-10 was measured in TSCs culture 
supernatants. Cytokine synthesis by untreated TSCs may mirror the activity of TSCs in situ. 
At 24 h after CLP and sham operation, spleens were removed and TSCs were prepared. 
Thereafter, TSCs were cultured and after 18 h of culture, supernatants were analyzed for 
the release of TNF-α and IL-10. The results showed that TSCs from control mice secreted 
no or negligible TNF-α and IL-10. In contrast, TSCs from septic mice released elevated 
amounts of TNF-α and IL-10 (Fig. 37).  
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Figure 37: Synthesis of TNF-α 
and IL-10 during sepsis. 
Twenty-four hours after CLP or 
sham operation, spleens were 
removed and splenocytes were 
pooled (n=3 to 4 per group) and 
were cultured for 18 h. 
Supernatants were analyzed for 
TNF-α and IL-10. Data show 
mean ± SD and are 
representative of 4 to 8 
independent experiments. 
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For checking the IFN- γ release during sepsis, TSCs were prepared and cultured with or 
without Con A for 48 h. Thereafter, supernatants were analyzed for IFN-γ. There was no or 
very little IFN-γ production by unstimulated TSCs from control and septic mice (Fig. 38). 
In contrast, the release of IFN-γ was increased upon stimulation both in control and septic 
mice but septic mice showed reduced capacity of producing IFN-γ compared to control 
mice (Fig. 38). Taken together, during polymicrobial sepsis TSCs develop altered cytokine 
secretion pattern with a predominance of IL-10 release. 
 
 
 
 
 
 
 
 
3.2.6. BMDCs Transfer Reduces IL-10, TNF-α and IFN-γ Production 
during Sepsis 
It is known that IL-10 production correlates with a Th2 type response and might contribute 
to immunosuppresion during sepsis. Therefore, the question concerning the modulation of 
this immunoregulatory cytokine upon BMDCs transfer was addressed. At 6 h after CLP or 
sham operation, control mice and one group of septic mice were injected with PBS and 
another group of septic mice were injected with CpG oligonucleotides stimulated wildtype 
BMDCs. Eighteen hours after injections, spleens were removed and TSCs were prepared. 
Thereafter, TSCs were cultured without any stimulus for 18 h and supernatants were 
analyzed for IL-10. TSCs from control mice injected with PBS [Control (P)] released no 
IL-10. In contrast, TSCs from septic mice injected with PBS [CLP (P)] produced elevated 
amounts of IL-10. However, this increased IL-10 production was decreased in TSCs from 
septic mice injected with CpG stimulated wildtype BMDCs [CLP (B+C)] compared to CLP 
(P) mice (Fig. 39). 
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Figure 38: Synthesis of IFN-γ during 
sepsis. Twenty-four hours after CLP or 
sham operation, spleens were removed 
and splenocytes were pooled (n=3 to 4 
per group) and were cultured with or 
without Con A for 48 h. Supernatants 
were analyzed for IFN-γ. Data show 
mean ± SD and are representative of 
seven independent experiments. 
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Further, the effect of BMDCs transfer on the capacity of TSCs to produce TNF-α, which is 
one of the most potent inducers of inflammation, was analyzed. Therefore, the supernatants 
generated for IL-10 analysis (as mentioned above) were also analyzed for TNF-α 
production. TSCs from control (P) mice released no or negligible TNF-α. In contrast, 
unstimulated TSCs from CLP (P) treated mice produced substantial amounts of TNF-α. 
However, this increased TNF-α  production was decreased in TSCs from CLP (B+C) 
treated mice compared to CLP (P) treated mice (Fig. 40).  
 
 
 
 
 
 
 
 
 
 
 
Next, the effect of BMDCs transfer on the capacity of TSCs to produce IFN-γ, which is a 
known Th1 cytokine, was tested. Therefore, TSCs from control (P), CLP (P), and CLP 
(B+C) were prepared and cultured with Con A for 48 h. Thereafter, supernatants were 
tested for IFN-γ. In response to Con A, TSCs from control (P) mice released high levels of 
IFN-γ in comparison with TSCs from CLP (P) treated mice which showed reduced capacity 
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Figure 39: Reduction in IL-10 production 
on transfer of CpG stimulated wildtype 
BMDCs during sepsis. Twenty-four hours 
after CLP or sham operation, spleens were 
removed and splenocytes were pooled (n=3 
to 4 per group) and were cultured for 18 h. 
Supernatants were analyzed for IL-10. 
Data show mean ± SD and are 
representative of six independent 
experiments. 
 
Figure 40: Reduction in TNF-α 
production on transfer of CpG 
stimulated wildtype BMDCs during 
sepsis. Twenty-four hours after CLP 
or sham operation, spleens were 
removed and splenocytes were 
pooled (n=3 to 4 per group) and 
were cultured for 18 h. Supernatants 
were analyzed for TNF-α. Data 
show mean ± SD and are 
representative of five independent 
experiments. 
 61 
of producing IFN-γ. Furthermore, this decreased IFN-γ production was decreased in TSCs 
from CLP (B+C) treated mice compared to CLP (P) treated mice (Fig. 41). Taken together, 
during sepsis transfer of BMDCs into CLP treated mice reduce IL-10, TNF-α and IFN-γ 
production by total spleen cells. 
 
 
 
 
 
 
 
 
 
3.2.7. IL-12 is not Responsible for Reduced IL-10 Production on BMDCs 
Transfer during Sepsis 
It has been reported that IL-12 induces the generation of Th1 type cells producing IFN-γ 
and IL-2 and at the same time, IL-12 inhibits the generation of Th2 cells, which produce 
IL-10 and IL-4. Thus, the putative role of IL-12 in reduced IL-10 synthesis was 
investigated. Therefore, BMDCs from IL-12p35-/- (IL-12-KO) mice, which show impaired 
IL-12 formation, were also generated. At 6 h after CLP or sham operation, CLP treated 
mice were divided into three groups. The control mice group and one group of septic mice 
were injected with PBS and the remaining two groups of septic mice were injected with 
CpG stimulated wildtype BMDCs and CpG stimulated IL-12-KO BMDCs separately. 
Eighteen hours after injections, spleens were removed and TSCs were prepared. TSCs were 
then cultured without any stimulus for 18 h and supernatants were analyzed for IL-10. 
TSCs from control mice injected with PBS [Control (P)] released no IL-10. In contrast, 
TSCs from septic mice injected with PBS [CLP (P)] produced enhanced levels of IL-10. 
However, this increased IL-10 production was decreased in both TSCs from septic mice 
injected with CpG stimulated wildtype BMDCs [CLP (B+C)] and TSCs from septic mice 
injected with CpG stimulated IL-12-KO BMDCs [CLP (B+C) KO] compared to CLP (P) 
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Figure 41: Reduction in IFN-γ production on 
transfer of CpG stimulated wildtype BMDCs 
during sepsis. Twenty-four hours after CLP 
or sham operation, spleens were removed and 
splenocytes were pooled (n=3 to 4 per group) 
and were cultured with Con A for 48 h. 
Supernatants were analyzed for IFN-γ. Data 
show mean ± SD and are representative of 
seven independent experiments. 
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mice (Fig. 42). Thus, IL-12 did not attribute to the reduced IL-10 production by total spleen 
cells on BMDCs transfer into CLP mice. 
 
 
 
 
 
 
 
 
 
 
Figure 42: IL-12 did not affect the 
reduced IL-10 production on transfer 
of CpG stimulated BMDCs. Twenty-
four hours after CLP or sham 
operation, spleens were removed and 
splenocytes were pooled (n=3 to 4 per 
group) and were cultured for 18 h. 
Supernatants were analyzed for IL-10. 
Data show mean ± SD and are 
representative of two independent 
experiments. 
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4. Discussion 
 
4.1. Characterization of Dendritic Cells during Sepsis 
Immunosuppression following sepsis syndrome remains a poorly understood phenomenon. 
DCs are known to play a pivotal role in the maintenance and development of cell-mediated 
immunity against invading pathogens. In the present study, it was hypothesized that the 
normal behavior and functional properties of DCs get changed during sepsis and might 
contribute to the immunosuppressed state of the host. It was shown that polymicrobial 
sepsis induced strong maturation of splenic DCs and a deviated cytokine secretion pattern 
of these DCs towards IL-10. This maturation process was not restricted to the spleen as a 
main secondary lymphoid compartment but was also observed in lymph nodes distant to the 
site of infection. However, maturation of DCs from lymph nodes of septic mice followed a 
slightly delayed kinetics in comparison to splenic DCs. Additionally, the present study 
provides evidence that splenic CD4+CD8- and CD4-CD8+ DCs subpopulations were 
selectively lost during disease development and that remaining DCs from septic mice were 
less potent in their capacity for T cell activation. 
 
A variety of components released from Gram-negative as well as Gram-positive bacteria, 
e.g. LPS, PGN etc. have been shown to induce maturation of DCs (De Smedt et al., 1996; 
Christensen et al., 2002; Reis e Sousa et al., 1999; Riva et al., 1996). Indeed, it has been 
reported that intraperitoneal bacteria rapidly reach liver and spleen via the blood circulation 
(Benacerraf et al., 1959). In addition, bacteria were detected in the spleen as early as 4 h 
after CLP (Table 2). From the peritoneal site of infection direct bacterial spreading via the 
peritoneal cavity or via the blood circulation may be responsible for the rapid maturation of 
splenic DCs (Fig. 16, 17, 18 19 and 20). In contrast, DCs from the popliteal or inguinal 
lymph nodes that do not drain the initial site of infection show a delayed kinetics of 
maturation (Fig. 21).  
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Recently, Ding et al. reported that peritoneal and splenic DCs do not enhance the 
expression of CD86 or CD40 upon CLP-induced sepsis within 24 h (Ding et al., 2004). 
This observation is in marked contrast to the present findings. However, they also report a 
lower IL-12 production in splenic DCs from septic mice, which is in alignment with the 
present findings. Different results in terms of DCs surface marker expression might be 
explained by different gating strategies during FACS analysis. Another possible 
explanation for these partially contradictory results is the fact that the inbred strain they 
used (C3H/HeN) might be less susceptible for sepsis (Watanabe et al., 2004). Efron et al. 
reported that the total number of DCs in popliteal and inguinal lymph nodes decreases 
within 24 h after CLP-induced sepsis without any signs for maturation in this time frame. 
The present data confirm the absence of DCs maturation at least during the early phase of 
sepsis up to 8 h (Efron et al., 2004). Only marginal effects in terms of DCs maturation was 
observed by 15 h after CLP, while obvious maturation of lymph node DCs was detected by 
36 h after CLP (Fig. 21).  
 
The present study could demonstrate that sepsis did not only induce profound maturation of 
DCs but also modulated splenic DCs in terms of cytokine secretion. It has been reported 
that upon bacterial or parasitic infection, DCs secrete a variety of pro-inflammatory 
cytokines such as IL-1, IL-12, TNF-α (Kadowaski et al., 2000; Langhorne et al., 2004; 
Pietila et al., 2005) and IFN-γ (Fricke et al., 2006; Ohteki et al., 1999; Pietila et al., 2005; 
Suzue et al., 2003). These reports are in alignment with the studies in which it was 
observed that secretion of pro-inflammatory cytokines by DCs and other leukocytes are 
needed in order to combat the invading pathogen (Tosi, 2005). But in the present study, as 
early as 8 h after CLP, splenic DCs from septic mice released lower levels of TNF-α and 
IFN-γ, when stimulated with LPS+CD40L or CpG and the levels of these cytokines 
decreased further up to 36 h after CLP (Fig. 22). It was reported that monocytes isolated 
from septic patients when cultured in the presence of LPS showed impaired production of 
pro-inflammatory cytokines such as IL-1, TNF-α and IL-6 (Munoz et al., 1991). Later on, 
such altered behavior of monocytes was termed as “monocyte deactivation” which leads to 
“immunoparalysis” and consequently to the death of the host (Volk et al., 1996; Docke et 
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al., 1997). Thus, one might speculate that the depressed response of TNF-α and IFN-γ by 
DCs during sepsis might be the result of their functional reprogramming similar to 
“monocyte-deactivation”. The pathophysiological mechanism leading to 
“immunoparalysis” is not yet fully understood. Interleukin-10, TGF-β, and PG 
(prostaglandin) E2 are known inhibitors of TNF-α and IFN-γ synthesis and might play a 
role in the development of “immunoparalysis” during sepsis. It has also been reported that 
the rapid release of IL-10 during endotoxemia that is often used as a model for sepsis in 
mouse controls TNF-α and IFN-γ production in vivo (Marchant et al., 1994). In accord with 
this study, we can herein suggest that soluble mediators like IL-10, TGF-β or PGE2 which 
are released locally in the tissue at high amounts during endotoxic shock (Randow et al., 
1995) and sepsis (Cohen, 2002) and therefore, might suppress the capacity of DCs to 
release pro-inflammatory cytokines like TNF-α, IFN-γ, but also IL-12.  
 
Within 4 to 8 h after CLP, splenic DCs lose their capacity to secrete bioactive IL-12 in 
response to LPS+CD40L or CpG that both are well known inducers of IL-12 (Fig. 24). DCs 
secrete IL-12 only transiently for approximately 16 h after stimulation (Langenkamp et al., 
2000) before they become unresponsive to further restimulation. This characteristic has 
been termed “exhaustion” of DCs and might represent a mechanism for protection from 
infection-induced immunopathology caused by unregulated IL-12 production. A state of 
impaired IL-12 secretion by splenic DCs upon restimulation with microbial components 
has been reported for DCs in other models of infectious diseases (Andrews et al., 2001; 
Reis e Sousa et al., 1999). However, such an immunosuppressive state reported for splenic 
DCs in the above mentioned models of infection is preceded by a transient phase of IL-12 
release and might be explained by DCs exhaustion. The present observations are in contrast 
to the findings in the above mentioned models of infection since unresponsiveness to 
restimulation of splenic DCs during sepsis was determined but not a preceding phase of IL-
12 secretion. Instead, DCs from septic mice secreted prominent levels of IL-10 ex vivo that 
were further enhanced upon stimulation with otherwise IL-12-inducing agents (Fig. 24). 
The reason for this aberrant cytokine response of splenic DCs during sepsis remains 
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unknown. Taken together, during sepsis splenic DCs fail to secrete TNF-α, IFN-γ and IL-
12 which are required for the induction of immunity against bacterial infections. 
 
Drug-mediated inhibition of IL-10 several hours after CLP has been associated with 
significantly increased pro-inflammatory cytokines like IFN-γ and improved bacterial 
clearance (Kalechman et al., 2002). In another study, in vivo neutralization of IL-10 
partially reversed the impairment in alveolar macrophage pro-inflammatory cytokine 
production and phagocytic activity (Reddy et al., 2001). In the present study, DCs-derived 
IL-10 seemed not to be responsible for suppressed IL-12 production since neutralization of 
IL-10 did not restore IL-12 production by splenic DC from septic mice (Fig. 26). Therefore, 
one might speculate that the response of splenic DCs after CLP is influenced by factors 
other than, or in addition to, IL-10.  
 
Interestingly, sepsis seems not to be associated with a general inhibition of IL-12 
production by DCs since it has been reported that DCs in the peritoneal cavity secrete 
substantial amounts of IL-12 during sepsis (Ding et al., 2004). The underlying mechanisms 
for this compartment-dependent IL-12 release by DCs remain unclear. We suggest that 
there exist differences in local micro-environmental factors between spleen and peritoneal 
cavity during sepsis that might cause different responses of DCs to bacteria. Potential 
candidates for such factors could be PGE2, IL-10, and TGF-β that are known to suppress 
IL-12 production by DCs (Kalinski et al, 1999). IL-10 and PGE2 have been found in serum 
and/or spleen early during sepsis (Emmanuilidis et al., 2001; Ertel et al., 1991). PGE2 
inhibits the release of IL-12 by DCs stimulated with bacterial products but does not affect 
the up-regulation of co-stimulatory molecules (Harizi et al., 2002). In contrast, IL-10 
inhibits both IL-12 synthesis and maturation of DCs (De Smedt et al., 1997; Steinbrink et 
al., 1997). Since splenic DCs from septic mice showed both maturation and suppression of 
IL-12 synthesis (Fig. 16 and 24), it is unlikely that circulating IL-10 alone mediates the 
development of the deviated DCs function during sepsis as describe here. Rather, it could 
be hypothesized that DCs in the peritoneal cavity, representing the primary site of infection, 
are directly stimulated by gut-derived microbes and are able to respond with adequate IL-
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12 production. In contrast, splenic DCs previously exposed to sepsis-induced mediators 
such as circulating PGE2 are therefore instructed for an impaired IL-12 secretion when 
stimulated by spreading bacteria or circulating bacterial products. 
 
Evidence for compartmentalization of the cytokine release during CLP-induced sepsis has 
also been described for the release of IFN-γ. Mononuclear cells from liver and from the 
peritoneal cavity but not from the spleen produce IFN-γ (Seki et al., 1998). This 
compartmentalization of cytokine production might explain why i.v. application of an 
adenoviral vector coding for IL-10 fails to improve survival after CLP whereas s.c. 
application protects from CLP-induced mortality (Oberholzer et al., 2002). Splenic DCs 
seem to be predisposed for IL-10 secretion during sepsis (Fig. 24). Thus, additional IL-10 
applied via the i.v. route would further support the predominance of anti-inflammatory 
mediators in the spleen. In this context it would be of interest whether DCs from peripheral 
lymph nodes of septic mice are impaired in IL-12 secretion as we observed for splenic DCs. 
However, the low number of lymph node DCs especially in septic mice was not sufficient 
for setting up the required cell cultures. Therefore, the behavior of lymph node DCs 
remains unknown. 
 
It has been shown that IFN-γ can increase the ability of cells to produce IL-12 (Ma et al., 
1996). In the present study, IFN-γ treatment of splenic DCs partially restored the decreased 
IL-12 production in the presence of CpG, only 3 h after CLP but not at 6 and 24 h after 
CLP while splenic DCs from sham-treated animals showed increased IL-12 production at 
all time points (Fig. 27). It has been reported that exogenous IFN-γ applied to septic 
patients restores the LPS-induced TNF-α secretion by monocytes in vitro (Docke et al., 
1997). In another study Mycobacterium leprae-stimulated monocytes produced increased 
amounts of IL-12 when treated with exogenous IFN-γ (Libraty et al., 1997). These reports 
contradict the present findings where IFN-γ treatment of splenic DCs only partially restored 
the IL-12 production. We suggest here that there might be some defect in IFN-γ sensing by 
splenic DCs during sepsis e.g. through downregulation of the IFN-γ receptor (IFN-γR) 
which renders them hyporesponsive or largely insensitive when treated with exogenous 
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IFN-γ. This assumption is in alignment with the report where Kalinski and coworkers have 
shown that mature DCs express reduced levels of IFN-γR and show decreased production 
of IL-12 in response to IFN-γ (Kalinski et al., 1999). In another study, it has been reported 
that when IFN-γR-deficient (IFN-γR-/-) mice were infected with Listeria monocytogenes, 
the mutant mice were unable to mount a proper innate immune response against bacterial 
growth and succumbed to sepsis (Dai et al., 1997). These reports suggest that recognition of 
IFN-γ is critical for the regulation of cellular responses during infection. Further studies 
will enhance our understanding of DCs unresponsiveness towards IFN-γ during sepsis. 
 
The present study shows the spontaneous release of MCP-1 by splenic DCs during late 
sepsis which gets reduced upon stimulation with LPS+CD40L or CpG (Fig. 28). It has been 
reported that following CLP, the levels of MCP-1 were increased in various tissues 
(Matasukawa et al., 2000; Benjamim et al., 2003). The elevated levels of MCP-1 have been 
detected in plasma of patients with sepsis (Bossink et al., 1995), as well as after 
administration of endotoxin to experimental animals or human volunteers (Jansen et al., 
1995; Sylvester et al., 1993). With the understanding of these reports one could say that the 
cells present in the circulation and tissues become a major source of MCP-1 during sepsis. 
This release of MCP-1 during CLP-induced sepsis or endotoxic shock has been shown to be 
associated with the increased survival of the animal (Matsukawa et al., 1999; Zisman et al., 
1997). Indeed, in the present study, splenocytes were able to produce MCP-1 36 h after 
CLP while no/negligible MCP-1 was released at 8 and 15 h after CLP (data not shown). 
This MCP-1 might be produced by DCs present in total population of spleen cells, as 
similar pattern for MCP-1 release was observed for splenic DCs (Fig. 28). Following 
maturation DCs are known to produce MCP-1 (Sallusto et al., 1998; Sozzani, 2005). This is 
in accord with the present finding where mature splenic DCs released elevated amounts of 
MCP-1 36 h after CLP. Here, one might argue that splenic DCs showed maturation at 8 and 
15 h after CLP also but there was no MCP-1 released at those time points. This can be 
explained by the observation that at 36 h after CLP, CD4-CD8- became a main 
subpopulation of DCs and it might represent the main subpopulation of DCs for the 
production of MCP-1. This assumption is further supported by the recent study where CD4-
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CD8- DCs were shown to secrete different amounts of cytokines like TGF-β, IFN-γ and 
TNF-α secretion as compared to CD4+CD8- and CD4-CD8+ DCs (Zhang et al., 2005). 
Therefore, it is tempting to speculate that these DCs subpopulations might vary in the 
release of MCP-1. 
 
It has been shown that MCP-1 can suppress IL-12 production by human monocytes (Braun 
et al., 2000) and monocyte derived DCs (Omata et al., 2002). Here, one might assume that 
MCP-1 could have a same effect on mouse splenic DCs as seen with monocytes or 
monocyte derived DCs. But this assumption is in partial variance with the present findings 
where splenic DCs showed suppressed IL-12 production capacity in vitro even in the 
absence of MCP-1 during early sepsis (Fig. 24). Therefore, one could imagine that besides 
MCP-1 there might be other factors which contribute to the suppressed IL-12 production. 
 
In addition, the release of MCP-1 by splenic DCs was coinciding with the release of IL-10 
at 36 h after CLP. Here, one might assume that they both influence the release of each 
other. This assumption is in accord with the present findings where splenic DCs released 
predominant levels of IL-10 with increase in MCP-1 release at 36 h after CLP. But on the 
same hand it partly contradicts the findings of IL-10 release, though very little, without any 
release of MCP-1 by splenic DCs. Therefore, it’s difficult to predict that they influence the 
release of each other. Further studies are needed to elucidate the underlying mechanisms of 
their release. 
 
The predominance of IL-10 supported by increased release of MCP-1 from splenic DCs 
during sepsis as shown here might polarize Th cells towards Th2 and in parallel might 
inhibit the development of a Th1 response that is required for the effective clearance of 
bacterial infections (Corinti et al., 2001; Omata et al., 2002). The finding that splenocytes 
from septic mice secrete elevated levels of Th2 cytokines upon mitogenic stimulation 
(Ayala et al., 1994) support this assumption. The suppressive activity of IL-10 on Th1 cell 
polarization and proliferation might explain the unexpected finding that DCs from septic 
mice were inferior to DCs from controls in T cell activation despite the expression of high 
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levels of co-stimulatory molecules (Fig. 29). Another explanation for the reduced T cell 
stimulation in response to DCs from septic mice could be the activity of T regulatory (Treg) 
cells. These Treg cells can inhibit the proliferation and cytokine release of antigen-specific 
Th1 cells. It has been reported that Treg cells can be induced by “semi-mature” DCs that 
express MHC class II and CD86 molecules but fail to secrete pro-inflammatory cytokines 
(Akbari et al., 2001; McGuirk et al., 2002). Therefore, it is tempting to speculate that 
“semi-mature” DCs develop in the spleen during sepsis and activate Treg cells thereby 
preventing the induction of a protective Th1 immune response. This hypothesis is 
supported by the observation that elevated numbers of Treg cells were found in septic 
patients (Monneret et al., 2003). 
 
One might speculate that the reduced T cell-stimulatory capacity and the impaired IL-12 
production by DCs observed 36 h after CLP is a phenomenon characteristic for CD4-CD8- 
DCs. However, several reports argue against divergent properties of the splenic DCs 
subpopulations with regard to maturation and T cell activation (Maldonado-Lopez et al., 
2001; Edwards et al., 2002). Moreover, the finding that splenic DCs failed to secrete IL-12 
even during the early phase of sepsis (8 h after CLP, Fig. 24) when all DCs subtypes were 
present (Fig. 15B) further contradict the assumption of a CD4-CD8- DCs restricted 
phenomenon. 
 
During late sepsis, the number of splenic DCs expressing CD11c was strongly reduced. 
CD11c is a stable population marker for murine DCs and its expression remains unchanged 
upon maturation. So far, there is no evidence that DCs downregulate CD11c expression in 
vitro or in vivo. Therefore, we assume that the reduced number of splenic CD11c+ cells 
shown here represents a loss of DCs similar to the loss of CD11c+ DCs that has been 
observed e.g. during sepsis, endotoxemia, and viral infections (Tinsley et al., 2003; De 
Smedt et al., 1996; Montoya et al., 2005). It was further shown here that the reduced 
number of splenic DCs during late sepsis is mediated by a selective loss of the CD4+CD8- 
and CD4-CD8+ DC subpopulations. In contrast, the total number of CD4-CD8- DCs 
remained unaffected and CD4-CD8- DC became a main subpopulation by 36 h after CLP 
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(Fig. 15). The three DC subpopulations arise from distinct DC lineages and in vivo there is 
no conversion of one subtype into another e.g. through downregulation of CD4 or CD8 
expression (Kamath et al., 2002). Likewise, CD4+ or CD8+ DC remain clearly positive for 
these markers even upon maturation in vitro (Vremec et al., 2000). Thus, it is assumed that 
the CD4+CD8- and CD4-CD8+ DCs are lost during sepsis rather than that these subtypes 
transform into CD4-CD8- DCs.  
 
The disappearance of two DCs subsets during sepsis may occur through migration and/or 
death. Since apoptosis of DCs has already been reported to be associated with sepsis (both 
in humans and in mice) (Hotchkiss et al., 2002; Tinsley et al., 2003; Efron et al., 2004), it is 
supposed that the selective loss of CD4+CD8- and CD4-CD8+ DCs that are shown here is 
the consequence of apoptosis. It is well known that DCs undergo apoptosis after reaching 
the final maturation stage e.g. upon administration of LPS (De Smedt et al., 1998). Such a 
programmed DCs death might represent a tool for regulation of the immune response. 
However, in this study an enhanced maturation stage of CD4+CD8- and CD4-CD8+ DCs in 
comparison to CD4-CD8- DCs that could result in the predominant loss of these DCs 
subtypes was never observed (data not shown). Thus, the mechanisms of selective DCs 
subset depletion remain speculative.  
 
In summary, in the present study a profound maturation of DCs during polymicrobial sepsis 
was observed. However, DCs acquire a phenotype that might favor the development of Th2 
and/or Treg cells and might inhibit effective immunity against the bacterial infection 
through Th1 cell polarization. Changes in DCs phenotype or functions could therefore 
contribute to sepsis-mediated immunosuppression. Treatment regimens that restore the 
capacity of DCs for Th1 cell polarization or the regular DCs number seem to represent 
promising approaches to counteract immunoparalysis during sepsis. Indeed, the instillation 
of competent DCs into the lungs of postseptic mice restored an effective antifungal host 
response in the lung (Benjamim et al., 2005). An attempt to use stimulated DCs as a 
therapeutic agent during acute sepsis is discussed in the second part of this chapter (section 
4.2). 
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4.2. Restoration of Dendritic Cell Functions during Sepsis 
The aim of the second part of this study was to set up a therapy that might prevent the 
development of sepsis-associated immunosuppression. Based on the previous findings of 
aberrant DCs function (see section 3.1) during sepsis and on the recent report on the 
essential role of DCs (Scumpia et al., 2005), a treatment regimen was established. Septic 
mice were treated with in vitro generated competent BMDCs that should overcome the 
inability of endogenous DCs to mount a Th1-type immune response. Therefore, BMDCs 
secreting IL-12 and expressing co-stimulatory molecules are required. The BMDCs were 
treated with CpG for 8 h prior to injection in order to ensure IL-12 secretion and maturation 
at the time point of application. Moreover, prior induction of maturation of DCs can not be 
stopped or reversed once the maturation machinery has started. It means that there is a 
“point of no return” in the life cycle of DCs. Therefore, BMDCs were previously matured 
before injecting them into the septic animal. These mature BMDCs are not sensitive to 
“suppressive milieu” present in septic animal that might be responsible for aberrant 
function of endogenous DCs. This therapy resulted in the diminished loss of TSCs number 
and in reduced IL-10 production by these cells. The diminished loss of TSCs number was 
associated with an increased total T cell number in the spleen. In addition to the reduced 
IL-10 production by TSCs mediated by the treatment with BMDCs, a reduced secretion of 
TNF-α and IFN-γ was also observed. The present study also provides evidence that reduced 
IL-10 production by TSCs was not dependent on the IL-12 secreted by injected BMDCs. 
 
It has been documented that CD11c+ DCs are required for survival in murine polymicrobial 
sepsis (Scumpia et al., 2005). In the present study, we tested the hypothesis that transfer of 
ex vivo generated BMDCs might modulate the immune status of septic mice and might 
prevent the development of sepsis-induced immunosuppression.  
 
The present study also demonstrates a marked loss in the number of TSCs 24 h after CLP 
(Fig. 35). The loss of TSCs during sepsis may occur through death. Since apoptosis of 
leukocyte has already been reported to be associated with sepsis (both in humans and in 
mice) (Hotchkiss et al., 2003; Wesche et al., 2005), we suppose that the loss of TSCs that 
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are shown here is the consequence of apoptosis. The loss in number of TSCs during sepsis 
was associated with the loss in number of total T cells (Results section 4.2.4.2.). This 
finding is in accordance with the reports of Hotchkiss and coworkers, where they have 
shown an increase in splenic lymphocyte apoptosis in septic mice, which was associated 
with an increase in mortality (Hotchkiss et al., 1997; Hiramatsu et al., 1997). Besides 
lymphocytes many other cell types in the lymphoid organs undergo apoptotic loss during 
sepsis (Wesche et al., 2005). In the present study, we have observed the loss in number of 
two DCs subtypes (as discussed earlier) and total T cells. Such a change in the number of 
specific immune cells might contribute to altered immune response and decreased ability of 
host to ward off the lethal effects of sepsis. 
 
As discussed in the last paragraph, the loss of TSCs during sepsis is mediated through 
apoptosis. Since the application of BMDCs was performed at 6 h after CLP when TSCs 
numbers are unchanged between septic and sham mice, it is more likely that the therapy 
with BMDCs prevented apoptosis rather than that it induced proliferation. The mechanism 
how injection of BMDCs might prevent apoptosis-induced cell death in the spleen remains 
speculative. It has been shown here that treatment with BMDCs results in reduced secretion 
of TNF-α by TSCs. It is well known that TNF-α triggers the extrinsic pathway of apoptosis 
via binding to the death receptor TNFR1 (Chen et al., 2002; Cunningham et al., 2002).  
 
 
 
 
 
 
 
 
 
 
Figure 43: Engagement of TNF-α with 
its cognate receptor TNFR1, which in 
turn triggers the apoptotic pathway. 
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This pathway might be relevant during sepsis development since it was shown that TNF-α 
mediates apoptosis in the tissue in a TNFR1-dependent manner (Oberholzer et al., 2001). 
Although these data are conflicting with the work of Ebach et al. who reported that the 
TNFR1 is irrelevant for the sepsis-associated induction of apoptosis in tissues like spleen 
and thymus (Ebach et al., 2005). However, given an involvement of the TNFR1 in 
apoptosis during sepsis, the reduced secretion of TNF-α by TSCs from BMDCs-treated 
mice in comparison to untreated septic mice might result in decreased TNF-α-induced 
apoptosis. Certainly, there might exist other mechanisms how the therapy with BMDCs 
might prevent apoptosis and further studies are needed to clarify them. 
 
In the present study, elevated levels of TNF-α and IL-10 and low levels of IFN-γ were 
produced by TSCs during sepsis (Fig. 37 and 38). Indeed, it has been reported that key pro-
inflammatory and immunomodulatory cytokines such as IL-1, IL-6, IL-10, or TNF-α are 
induced after activation of TLRs by microbial ligands (Krutzik et al., 2001). But the 
imbalance in their secretion might lead to poor clearance of invading pathogen as seen in 
septic patients. In patients with documented sepsis, coexistence of pro- and anti-
inflammatory cytokines have been documented in the circulation and presumably within 
the tissues (Goldie et al., 1995; Vanderpoll et al., 1997; Ertel et al., 1996). It was reported 
that the expression of TNF mRNA increased in the tissues like spleen, liver and lung 
following CLP-induced sepsis or intraperitoneal injection of endotoxin (Hadjiminas et al., 
1994). This is in alignment with the present findings where elevated levels of TNF-α were 
produced by TSCs following sepsis. Ayala and coworkers showed that CLP-induced sepsis 
causes decreased IFN-γ release while increasing IL-10 production by TSCs (Ayala et al., 
1994). This is consistent with the present finding where decreased levels of IFN-γ and 
increased levels of IL-10 were produced by TSCs following CLP-induced sepsis. Thus, 
present data confirm the dysregulated production of cytokines during the sepsis disease 
response. 
 
Treatment of septic mice with BMDCs did not only affect the sepsis-associated cell loss in 
the spleen but additionally modulated the above described aberrant cytokine pattern during 
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sepsis. Administration of BMDCs resulted in decreased production of IL-10, TNF-α and 
IFN-γ by TSCs (Fig. 39, 40 and 41). It has been reported that activated DCs following 
CD40 ligation or TLR ligation produced IL-12p70, which induces IFN-γ production and is 
important for the generation of Th1 cells (Boonstra et al., 2003). DCs that fail to produce 
IL-12p70 are assumed to promote the generation of a Th2 response or down-regulate Th1 
responses via the action of costimulatory molecules and/or other DCs produced cytokines 
such as IL-6 or IL-10 (Trembleau et al., 1997; Rincon et al., 1997; Rissoan et al., 1999; 
Diehl et al., 2002). These reports are consistent with the findings discussed in earlier 
section that the splenic DCs produced decreased IL-12 and increased IL-10 during sepsis 
and therefore, failed to initiate protective Th1 immune response against accumulating 
bacteria. The transfer of IL-12 secreting BMDCs resulted in the decreased production of 
IL-10 by splenocytes (Fig 39). This can be explained by the reason that the transfer of IL-
12 secreting BMDCs during sepsis might effectively prime the Th cells towards Th1 
response. The onset of Th1 response might result in the decreased production of IL-10 by 
TSCs. Also the transfer of IL-12 secreting BMDCs into septic mice leads to decreased 
production of IFN-γ by TSCs stimulated with Con A (Fig. 41). These findings were 
unexpected. In a very recent report it has been documented that the cytokine profile of the 
injected BMDCs plays a key role in the development of Th1 or Th2 response. The BMDCs 
which were cultured only in GM-CSF were able to secrete IL-12p70 but were unable to 
induce strong Th1 polarization (Feili-Hariri et al., 2005). This report might explain in part 
the findings of decreased IFN-γ secretion by TSCs upon transfer of GM-CSF cultured 
BMDCs. Another reason for decreased IFN-γ production by TSCs upon BMDCs injection 
could be the presence of a restricted number of IFN-γ secreting T cells in TSCs population. 
And the number of these cells remains constant even when there was diminished loss in T 
cell number upon BMDCs transfer. This might resulted in the dilution of IFN-γ 
concentration produced by restricted number of T cells as seen in the present findings. To 
elucidate this assumption in more detail, one has to examine the production of IFN-γ per 
cell by performing intracellular staining. Since, IFN-γ production was not analyzed per cell 
in the present study, therefore, the mechanism for decreased production of IFN-γ upon 
BMDCs transfer remains unknown. 
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The ability of DCs to induce Th1 differentiation has been related to their ability to produce 
high levels of IL-12p70. This is becoming relevant in clinical settings, where DCs are being 
used as therapy in the treatment of cancer for example (Schuler et al., 2003). Surprisingly, 
the treatment of septic mice with IL-12p35KO BMDCs resulted in the decreased 
production of IL-10 as shown by the transfer of wildtype BMDCs (Fig. 42). These findings 
suggest that IL-12p70 is not responsible for the decreased IL-10. Here, one might assume 
that there could be other factor(s) secreted by DCs which can contribute to the decreased 
IL-10 production by TSCs. The putative factor could be IFN-γ. It has been shown that 
BMDCs which secrete IFN-γ besides IL-12p70 possess a strong Th1-skewing capability 
(Feili-Hariri et al., 2005). Therefore, it is tempting to study the effect of the deletion of 
IFN-γ gene alone besides IL-12 gene or both in the outcome of sepsis response. 
 
Overall, these studies demonstrate that the transfer of DCs into the septic mice resulted in 
the change of spleen cytokine environment, representing a main secondary lymphoid organ 
located next to the site of infection. I was able to identify the effects of BMDCs transfer 
into the septic mice. BMDCs transfer resulted in diminished cell loss and decreased IL-10 
production by the spleen cells. These changes might favor the development of Th1 
response, which is required for the effective immunity against bacterial infection. Thus, one 
can say that DCs play a major role in linking the innate and adaptive systems and could 
serve as a potential tool to intervene in the disease process during sepsis. 
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5. Summary 
 
The present study comprises of two parts. The first part deals with studies on the role of 
DCs during polymicrobial sepsis and the second part includes the exploitation of BMDCs 
as therapeutic agents to prevent the sepsis-induced immunosuppression. 
 
The data obtained from the first part indicated that the sepsis induced altered phenotypic 
and functional changes in the splenic and the lymph node DCs. There was marked 
maturation of DCs in the spleen and in the lymph nodes but this process of maturation 
occurred later in lymph nodes than in the spleen. The splenic DCs developed an altered 
cytokine secretion pattern, which was associated with the inability of splenic DCs to 
produce Th1-type cytokines such as IL-12 but released high levels of IL-10. This 
impairment of IL-12 synthesis was independent from endogenously produced IL-10 as 
neutralization of IL-10 did not restore the IL-12 secretion by DCs. But IFN-γ treatment 
restored in part the IL-12 production by splenic DCs only during early sepsis. In addition, 
the splenic CD4+CD8- and CD4-CD8+ subpopulations were lost during sepsis, and the 
remaining DCs showed a reduced capacity for allogeneic T cell activation associated with 
decreased IL-2 synthesis. Thus, during sepsis DCs acquire a phenotype that might favor the 
development of Th2 and/or Treg cells and might inhibit effective immunity against the 
bacterial infection through Th1 cell polarization. 
 
The data obtained from the second part highlighted that the administration of competent 
BMDCs into septic mice changed the cytokine milieu in the spleen, representing a main 
secondary lymphoid organ situated near to the site of infection. The instillation of 
competent BMDCs resulted in the diminished loss of splenocytes and in reduced IL-10 
production by these cells. The diminished loss of splenocytes was associated with an 
increased total T cell number in the spleen. In addition to the reduced IL-10 production by 
splenocytes mediated by the administration of BMDCs, a reduced secretion of TNF-α and 
IFN-γ was also observed. Moreover, the reduced IL-10 production by splenocytes was not 
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dependent on the IL-12 secreted by injected BMDCs. These changes in the spleen cytokine 
environment might favor the development of a Th1 response, which is required for the 
effective immunity against the bacterial infection. 
 
The present findings reinforce the idea that DCs are affected by sepsis and their 
replacement has some potentially beneficial contributions to the host’s response to 
infectious challenge. The present data are also in accord with an emerging understanding of 
the critical role played by DCs in the development of the proper Th1/Th2 cytokine balance 
during sepsis syndrome in order to ward off the invading bacteria. Thus, these data suggest 
that DCs are critical cells at the boundary between the innate and adaptive immune 
response and play an important role in bacterial responses. 
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